Ebola Virus Antibodies and Binding Agents Derived Therefrom

Abstract

This disclosure relates to antibodies and antigen binding fragments that specifically bind Ebola virus particles. In certain embodiments, the antibodies and fragments are capable of treating or preventing an Ebola viral infection. In certain embodiments, the antibodies and antigen binding fragments are also contemplated for diagnostic methods and compositions related thereto.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62/364,986 filed Jul. 21, 2016. The entirety of this application is hereby incorporated by reference for all purposes.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED AS A TEXT FILE VIA THE OFFICE ELECTRONIC FILING SYSTEM (EFS-WEB)

[0003] The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 16008PCT ST25.txt. The text file is 102 KB, was created on Jul. 21, 2017, and is being submitted electronically via EFS-Web.

BACKGROUND

[0004] Ebolaviruses are in the family Filoviridae that cause severe fevers that typically leads to fatalities in humans. Thus, there is a need to identify improved therapeutic methods for treating or preventing Ebola virus infections.

[0005] ZMapp is a combination of monoclonal antibodies in testing for the treatment for Ebola virus disease. Qiu et al., Nature, 2014, 514 (7520): 47-53. See also WO2001/016183.

[0006] Martinez et al. report an Ebola mucin-like domain effect antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis. 2011, 204 Suppl 3:S825-32.

[0007] Murin et al. report structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci USA. 2014, 111(48):17182-7.

[0008] Flyak et al. report cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell. 2016, 164(3):392-405

[0009] Furuyama et al. report an antibody for pan-Ebolavirus therapy. Sci Rep. 2016, 6:20514.

[0010] References cited herein are not an admission of prior art.

SUMMARY

[0011] This disclosure relates to antibodies and antigen binding fragments that specifically bind Ebola virus particles. In certain embodiments, the antibodies and fragments are capable of treating or preventing an Ebola viral infection. In certain embodiments, the antibodies and antigen binding fragments are also contemplated for diagnostic methods and compositions related thereto. In certain embodiments, the antibodies are non-naturally occurring chimeric antibodies.

[0012] In certain embodiments, this disclosure relates to antibodies or antigen binding fragments comprising six complementarity determining regions (CDRs) or consensus sequences thereof, wherein the CDRs comprise the three light chain CDRs derived from an antibody selected from 5.1.10B3, 5.6.1A02, 2.1.1D05, 2.1.1D07, 9.6.3D06, 2.1.7G07, 9.6.3A06, 5.1.13G03, 5.6.c2618, 2.10.1E06, 9.6.1A09, 5.1.7D03 and wherein the CDRs comprise the three heavy chain CDRs derived from an antibody selected from 5.1.10B3, 5.6.1A02, 2.1.1D05, 2.1.1D07, 9.6.3D06, 2.1.7G07, 9.6.3A06, 5.1.13G03, 5.6.c2618, 2.10.1E06, 9.6.1A09, 5.1.7D03, and wherein the antibody or antigen binding fragment thereof specifically or immunospecifically binds to an epitope expressed in an Ebola virus particle.

[0013] In certain embodiments, the CDRs comprise

[0014] the three light chain CDRs of antibody 5.1.10B3 within SEQ ID NO: 1 DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWHQQKPGKAPKLLIYAASSLQSGVPSR FSGSGSGTDFTLTISSLQPEDFAIYYCQQSYISPFTFGPGTKVDIK; CDR 1 (SEQ ID NO: 11) RASQSISSFLN; CDR2 (SEQ ID NO: 12) AASSLQS; and CDR3 (SEQ ID NO: 13) QQSYISPFT; and

[0015] the three heavy chain CDRs of antibody 5.1.10B3 within SEQ ID NO: 2 EVQLVESGGGLVQPGGSLRLSCAASGFTFRSYDMHWVRQATGKGLEWVSAIGTAGDT YYPGSVKGRFTISRENAKNSLYLQMNSLRAEDTAVYYCARVRFGDTAVDYWGQGTLV TVSS; CDR 1 (SEQ ID NO: 14) FTFRSYDMH; CDR 2 (SEQ ID NO: 15) IGTAGDTYYP; and CDR 3 (SEQ ID NO: 16) VRFGDTAVDY.

[0016] In certain embodiments, the CDRs comprise

[0017] the three light chain CDRs of antibody 5.6.1A02 within SEQ ID NO: 3 DIVMTQSPRSLSVTPGEPASISCRSSQSLLHRNGYNYLDWYLQKPGQSPQLLIYLGSNRA SGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPSWTFGQGTKVEIK; CDR 1 (SEQ ID NO: 17) RSSQSLLHRNGYNYLD; CDR 2 (SEQ ID NO: 18) LGSNRAS; and CDR 3 (SEQ ID NO: 19) MQALQTPSWT; and

[0018] the three heavy chain CDRs of antibody 5.6.1A02 within SEQ ID NO: 4 EVQLVESGGGLIQPGGSLRLSCAASGFAVRSNYLSWVRQAPGKGLEWVSLIYSGGLTAY ADSVEGRFTISRDNSKNTLYLQMNSLRVEDTALYYCARVASSAGTFYYGMDVWGQGT TVTVSS; CDR 1 (SEQ ID NO: 20) FAVRSNYLS; CDR 2 (SEQ ID NO: 21) LIYSGGLTAYADSVEG; and CDR 3 (SEQ ID NO: 22) VASSAGTFYYGMDV.

[0019] In certain embodiments, the CDRs comprise

[0020] the three light chain CDRs of antibody 2.1.1D05 within SEQ ID NO: 5 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVYWYQQLPGTAPKWYGNSNRPSGV PDRFSGSKSGTSASLAITGLQAEDEADYYCQSFDSSLRDSWVFGGGTKLTVL; CDR 1 (SEQ ID NO: 23) TGSSSNIGAGYDVY; CDR 2 (SEQ ID NO: 24) GNSNRPS; and CDR 3 (SEQ ID NO: 25) QSFDSSLRDSWV, and

[0021] the three heavy chain CDRs of antibody 2.1.1D05 within SEQ ID NO: 6 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMNWVRQAPGKGLEWVGRIKSKTDG GAADYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYFCTTVYRYNYDSVWGQGT LVTVSS; CDR 1 (SEQ ID NO: 26) FTFSNAWMN; CDR 2 (SEQ ID NO: 27) RIKSKTDGGAADYAAPVKG; and CDR 3 (SEQ ID NO: 28) VYRYNYDSV.

[0022] In certain embodiments, the CDRs comprise

[0023] the three light chain CDRs of antibody 2.1.1D07 within SEQ ID NO: 7 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAFNRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQLYGSSPWTFGQGTKVEIK; CDR 1 (SEQ ID NO: 29) RASQSVSSSYLA; CDR 2 (SEQ ID NO: 30) GAFNRAT; and CDR 3 (SEQ ID NO: 31) QLYGSSPWT, and

[0024] the three heavy chain CDRs of antibody 2.1.1D07 within SEQ ID NO: 8 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMSWVRQAPGKGLEWVSGISGSGGITY YADSVRGRFTISRDNSKNTLYLRMNSLRAEDTAVYYCAKVGEYYDFWSGYSPFEYWG QGTL; CDR 1 (SEQ ID NO: 32) FTFSTYGMS; CDR 2 (SEQ ID NO: 33) GISGSGGITYYADSVRG; and CDR 3 (SEQ ID NO: 34) VGEYYDFWSGYSPFEY.

[0025] In certain embodiments, the CDRs comprise

[0026] the three light chain CDRs of antibody 9.6.3D06 within SEQ ID NO: 9 DIQMTQSPSTLSASVGDRVTITCRASQRINNLVAWYQQKPGKAPKVMIYDAS SLKSGVP SRFSGSGSGTEFTLTISSLQPDDFATYFCQQYDTDSGWTFGQGTKVEIK; CDR 1 (SEQ ID NO: 35) RASQRINNLVA; CDR 2 (SEQ ID NO: 36) DASSLKS; CDR 3 (SEQ ID NO: 37) QQYDTDSGWT, and

[0027] the three heavy chain CDRs of antibody 9.6.3D06 within SEQ ID NO: 10 EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYAMIWVRQAPGKGLQWVAGINKSGGRT YYADSVRGRFTISRDNSKNTLYLQMKSLRADDTAMYYCAKEGSPLSDVLLVAAPFGWF DPWGQGTLVTVSS; CDR 1 (SEQ ID NO: 38) FTFSKYAMI; CDR 2 (SEQ ID NO: 39) GINKSGGRTYYADSVRG; and CDR 3 (SEQ ID NO: 40) EGSPLSDVLLVAAPFGWFDP.

[0028] In certain embodiments, the CDRs comprise

[0029] the three light chain CDRs of antibody 2.1.7G07 within SEQ ID NO: 69 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAFNRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSPFTFGPGTKVDIK; CDR 1 (SEQ ID NO: 70) QSVSSSY; CDR2 (SEQ ID NO: 71) GAFNRAT; and CDR3 (SEQ ID NO: 72) QQYGRSPFT; and

[0030] the three heavy chain CDRs of antibody 2.1.7G07 within SEQ ID NO: 73 EVQLVESGGGLVQPGGSLRLSCAASGFAFSTYAMSWVRQAPGKGLEWVSAITGSGYST YYADSVKGRFTISGDNSKNTLYLQMNSLRAEDTALYYCAKVGEYYDFWSGYSPFDSW GQGTLVTVSS; CDR 1 (SEQ ID NO: 74) GFAFSTYA; CDR 2 (SEQ ID NO: 75) ITGSGYST; and CDR 3 (SEQ ID NO: 76) AKVGEYYDFWSGYSPFDS.

[0031] In certain embodiments, the CDRs comprise

[0032] the three light chain CDRs of antibody 9.6.3A06 within SEQ ID NO: 77 DIVMTQTPLSSAVTLGQPASISCRSSQRLVHSDGNTYLSWLHQRPGQPPRLLIYKVSLRFS GVPDRFSGSGAGTDFTLKISRVEAEDVGIYYCMQATQFPLTFGGGTKVEIK; CDR 1 (SEQ ID NO: 78) QRLVHSDGNTY; CDR 2 (SEQ ID NO: 79) KVSLRFS; and CDR 3 (SEQ ID NO: 80) MQATQFPLT; and

[0033] the three heavy chain CDRs of antibody 9.6.3A06 within SEQ ID NO: 81 EVQLLESGGGLVKPGGSLRLSCAASGFTFNEYMMNWVRQPPGKGLEWVSSISGTSTYIN YADSVKGRFTISRDNAKNSLYLQMNSLRSDDTAMYYCARGSTGGYWGQGTLITVS; CDR 1 (SEQ ID NO: 82) GFTFNEYM; CDR 2 (SEQ ID NO: 83) ISGTSTYI; and CDR 3 (SEQ ID NO: 84) GSTGGY.

[0034] In certain embodiments, the CDRs comprise

[0035] the three light chain CDRs of antibody 5.1.13G03 within SEQ ID NO: 85 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKVLIYSAFSLQNGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK; CDR 1 (SEQ ID NO: 86) QSISSYLN; CDR 2 (SEQ ID NO: 87) SAFSLQN; and CDR 3 (SEQ ID NO: 88) QQSYSTPRT; and

[0036] the three heavy chain CDRs of antibody 5.1.13G03 within SEQ ID NO: 89 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSTNWWSWVRQPPGKGLEWIGEIYHSGSTN YNPSLKSRVTISLDKSKDQFSLKLSSVTAADTAVYYCAYSNTWTGGWGQGTLVTVSS; CDR 1 (SEQ ID NO: 90) GSISSTNWWS; CDR 2 (SEQ ID NO: 91) HSGSTN; and CDR 3 (SEQ ID NO: 92) SNTWTGG.

[0037] In certain embodiments, the CDRs comprise

[0038] the three light chain CDRs of antibody 5.6.c2618 within SEQ ID NO: 93 EVVLTQSPVTLSLSPGERATLSCRASQSVSGYLAWYQQKPGQVPRLLIYDTSNRATGIPA RFSGSGSGTDFTLTISTIEPEDFAVYYCQQRSKWGVTFGGGTKVDIK; CDR 1 (SEQ ID NO: 94) QSVSGYLA; CDR 2 (SEQ ID NO: 95) DTSNRAT; and CDR 3 (SEQ ID NO: 96) QQRSKWGVT; and

[0039] the three heavy chain CDRs of antibody 5.6.c2618 within SEQ ID NO: 97 QVQLVQSGAEVKKPGASVNLSCKGSGYSFRTYYIHWVRQAPGQGLEWMGIINSSGGGT TYAQKFQGRVTMTRDTSTSTVYMELRSLKYEDTAMYYCARDRFPTVSGEPFAMDVWG QGTTVTVSS; CDR 1 (SEQ ID NO: 98) GYSFRTYYIH; CDR 2 (SEQ ID NO: 99) INSSGGGTTY; and CDR 3 (SEQ ID NO: 100) DRFPTVSGEPFAMDV.

[0040] In certain embodiments, the CDRs comprise

[0041] the three light chain CDRs of antibody 2.10.1E06 within SEQ ID NO: 101 EIVLTQSPGTLSLSPGERATLSCRASQSVTSNYLAWYQQKPGQAPRVLIYGASSRATGIP DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGASPPYSFGQGTKVEIK; CDR 1 (SEQ ID NO: 102) QSVTSNYLA; CDR 2 (SEQ ID NO: 103) GASSRAT; and CDR 3 (SEQ ID NO: 104) QQFGASPPYS; and

[0042] the three heavy chain CDRs of antibody 2.10.1E06 within SEQ ID NO: 105 EVQLVESGGGLIQPGGSLRLSCTASGFTFSKFAMSWVRQAPGRGLEWISYISGGSKTKY YADSVRGRFTISRDNAKGSLFLQMNSLRAEDTAIYFCAKKGWQSTFLGMDYFYGMDV WGKGTTVTVSS; CDR 1 (SEQ ID NO: 106) GFTFSKFAMS; CDR 2 (SEQ ID NO: 107) ISGGSKTKY; and CDR 3 (SEQ ID NO: 108) AKKGWQSTFLGMDYFYGMDV.

[0043] In certain embodiments, the CDRs comprise

[0044] the three light chain CDRs of antibody 9.6.1A09 within SEQ ID NO: 109 DIVMTQSPDSLAVSLGERASINCKSSQSVLSSSNTKNYLAWYQHKPGQPPKWYWAST RESGVPDRFSGSGSGTDFTLTISSLQPEDVAVYYCQQYYGAPYTFGQGTKVEIK; CDR 1 (SEQ ID NO: 110) QSVLSSSNTKNY; CDR 2 (SEQ ID NO: 111) WASTRES; and CDR 3 (SEQ ID NO: 112) QQYYGAPYT; and

[0045] the three heavy chain CDRs of antibody 9.6.1A09 within SEQ ID NO: 113 EVQLVESGGGLVQPGGSLRLSCAASGFTFRSYDMDWFRQSTGKGLEWVSAIGSAGDTY YTDSVKGRFTISRENGKNSLYLQMNSLRAGDTAVYYCARARFGDNVFDLWGRGTLVT VSS; CDR 1 (SEQ ID NO: 114) FTFRSYDMD; CDR 2 (SEQ ID NO: 115) IGSAGDT; and CDR 3 (SEQ ID NO: 116) ARFGDNVFDL.

[0046] In certain embodiments, the CDRs comprise

[0047] the three light chain CDRs of antibody 5.1.7D03 within SEQ ID NO: 117 EIVLTQSPGTLSLSPGERAALSCRASQSVSGNYFAWYQQKSGQAPRLLISAASSRATGVP DRFSASGSGTDFTLTISRLEPEDSAVYYCQQYGSSPLTFGQGTKVEIK; CDR 1 (SEQ ID NO: 118) SVSGNYFA; CDR 2 (SEQ ID NO: 119) AASSRAT; and CDR 3 (SEQ ID NO: 120) QQYGSSPLT; and

[0048] the three heavy chain CDRs of antibody 5.1.7D03 within SEQ ID NO: 121 EVQLVQSGGGLAQPGGSLRLSCAASGFTFRSYDMHWVRQVTGKGLEWVSAIGTAGDT YYTGSVKGRFTISRENDKSSLYLQMSSLRGEDTAVYYCARAAFGSHYFDYWGQGTLVT VSS; CDR 1 (SEQ ID NO: 122) FTFRSYDMH; CDR 2 (SEQ ID NO: 123) IGTAGDTYYT; and CDR 3 (SEQ ID NO: 124) AAFGSHYFDY.

[0049] In certain embodiments, an antibody or antigen binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 1, 3, 5, 7, 9, 69, 77, 85, 93, 101, 109, or 117 having at least 80, 85, 90, 95, 98, 99%, or more sequence identity or similarity thereto.

[0050] In certain embodiments, an antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 73, 81, 89, 97, 105, 113, or 121 having at least 80, 85, 90, 95, 98, 99%, or more sequence identity or similarity thereto.

[0051] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 11, 12, 13, 14, 15, and 16, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0052] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 17, 18, 19, 20, 21, and 22, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0053] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 23, 24, 25, 26, 27, and 28, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0054] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 29, 30, 31, 32, 33, and 34, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0055] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 35, 36, 37, 38, 39, and 40, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0056] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 70, 71, 72, 74, 75, and 76, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0057] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 78, 79, 80, 82, 83, and 84, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0058] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 86, 87, 88, 90, 91 and 92, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0059] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 94, 95, 96, 98, 99, and 100, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0060] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 102, 103, 104, 106, 107, and 108, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0061] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 110, 111, 112, 114, 115, and 116, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0062] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 118, 119, 120, 122, 123, and 124, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0063] In certain embodiments, this disclosure relates to antibodies or antigen binding fragments comprising six complementarity determining regions (CDRs) or consensus sequences thereof, wherein the CDRs comprise the three light chain CDRs derived from an antibody selected from 2.1.1B02, 5.24.1C11, 9.20.1C03, 5.24.1B03, 9.20.1D09, 5.24.2A03, 9.20.1A02, 5.24.2C05, 5.24.2B07 and wherein the CDRs comprise the three heavy chain CDRs derived from an antibody selected from 2.1.1B02, 5.24.1C11, 9.20.1C03, 5.24.1B03, 9.20.1D09, 5.24.2A03, 9.20.1A02, 5.24.2C05, 5.24.2B07, and wherein the antibody or antigen binding fragment thereof specifically or immunospecifically binds to an epitope expressed in an Ebola virus particle.

[0064] In certain embodiments, the CDRs comprise

[0065] the three light chain CDRs of antibody 2.1.1B02 within SEQ ID NO: 125 SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVPVIYKDSERPSGIPER FSGSSSGTTVTLTISGVQAEDEADYYCQSSDSSGTYVVFGGGTKLTVL; CDR 1 (SEQ ID NO: 126) ALPKQY; CDR2 (SEQ ID NO: 127) KDSE; and CDR3 (SEQ ID NO: 128) QSSDSSGTYVV; and

[0066] the three heavy chain CDRs of antibody 2.1.1B02 within SEQ ID NO: 129 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGS TSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARHDSSGYDAFDIWGQGTM VTVSS; CDR 1 (SEQ ID NO: 130) GYTFTSYY; CDR 2 (SEQ ID NO: 131) INPSGGST; and CDR 3 (SEQ ID NO: 132) ARHDSSGYDAFDI.

[0067] In certain embodiments, the CDRs comprise

[0068] the three light chain CDRs of antibody 5.24.1C11 within SEQ ID NO: 133 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYVDWYLQKPGQSPQLLIYLGSSRAS GVPDRFSGSGSGTDFTLKISRVETEDVGIYYCMQGLQTPLTFGGGTKVEIK; CDR 1 (SEQ ID NO: 134) QSLLHSNGYNY; CDR2 (SEQ ID NO: 135) LGSS; and CDR3 (SEQ ID NO: 136) MQGLQTPLT; and

[0069] the three heavy chain CDRs of antibody 5.24.1C11 within SEQ ID NO: 137 QVQLVQSGAEVKKPGASVKVSCRTSGYTFSSYNIHWVRQAPGQGLEWMGVINPYGRST TLYARRFRDRVTMTRDTSTSTVYMELSSLRSEDTAVYFCGRLYSGAPYGLDVWGQGST VTVSS; CDR 1 (SEQ ID NO: 138) GYTFSSYNIH; CDR 2 (SEQ ID NO: 139) PYGRSTT, and CDR 3 (SEQ ID NO: 140) GRLYSGAPYGLDV.

[0070] In certain embodiments, the CDRs comprise

[0071] the three light chain CDRs of antibody 9.20.1C03 within SEQ ID NO: 141 DIVLTQSPDSLAASLGERATISCKSSHSVLYSSNNKDFFAWYQQKPGQPPKLLISWASTR ESGVPVRFNGGGSGTHFTLTISSLQAEDVAVYYCQQYFSSPITFGQGTRLEIK; CDR 1 (SEQ ID NO: 142) HSVLYSSNNKDF; CDR2 (SEQ ID NO: 143) WAST; and CDR3 (SEQ ID NO: 144) QQYFSSPIT; and

[0072] the three heavy chain CDRs of antibody 9.20.1C03 within SEQ ID NO: 145 QVQLVQSGAEVKKPGSSVKVACKVSGGTFSSYTISWVRQAPGQGLEWMGGIIPSFGVG HYSQKFRDRVTLTADKSTTTAFLELSSVRSEDTALYYCAILGTFNWKSGGNYFGPWGQ GTLVTVSS; CDR1 (SEQ ID NO: 146) GGTFSSYT; CDR 2 (SEQ ID NO: 147) IIPSFGVG; and CDR 3 (SEQ ID NO: 148) AILGTFNWKSGGNYFGP.

[0073] In certain embodiments, the CDRs comprise

[0074] the three light chain CDRs of antibody 5.24.1B03 within SEQ ID NO: 149 EIVLTQSPNTLSLSPGERATLSCRASQSLRTNQLAWYQQKPGQAPRLLIHTSTRATGIPDR FSGSGSGTDFTLTISGLEAEDFAVYYCQASDTSSLTFGGGTKLEIR; CDR 1 (SEQ ID NO: 150) QSLRTN; CDR2 (SEQ ID NO: 151) HTST; and CDR3 (SEQ ID NO: 152) QASDTSSLT; and

[0075] the three heavy chain CDRs of antibody 5.24.1B03 within SEQ ID NO: 153 QVQLQESGPGLVKPSESLSLTCTISGGSIRDYYWSWIRQAPGKGLEWIGYKYHAARGNS NPSLESRVTMSIDTSRSEFSLRLTSVTAADTAVYYCARVQYGPGGGYYSGNWLDLWGQ GTLVTVSS; CDR 1 (SEQ ID NO: 154) GGSIRDYY; CDR 2 (SEQ ID NO: 155) KYHAARG; and CDR 3 (SEQ ID NO: 156) ARVQYGPGGGYYSGNWLDL.

[0076] In certain embodiments, the CDRs comprise

[0077] the three light chain CDRs of antibody 9.20.1D09 within SEQ ID NO: 157 EIVMTQSPATLSLSPGERASLSCRASQSIATNLAWYQQKPGQPPRVLIYGASTRATGIPTR FSGSGSGTEFTLTISSLQSEDFAIYYCHQYHSWRTFGQGTKVEMK; CDR 1 (SEQ ID NO: 158) QSIATN; CDR2 (SEQ ID NO: 159) GAST; and CDR3 (SEQ ID NO: 160) HQYHSWRT; and

[0078] the three heavy chain CDRs of antibody 9.20.1D09 within SEQ ID NO: 161 QLQLQESGPGLVKPSETLSLTCTVSGGSVASSNDYWGWIRQPPGKGPEWIGTIFYRGTTD YNPSLKSRLTMSVDTSRNQFSLKLSSVTAADTAVYYCARLPLWFSELGHDYWGQGTLV TVSS; CDR 1 (SEQ ID NO: 162) GGSVASSNDY; CDR 2 (SEQ ID NO: 163) IFYRGTT; and CDR 3 (SEQ ID NO: 164) ARLPLWFSELGHDY.

[0079] In certain embodiments, the CDRs comprise

[0080] the three light chain CDRs of antibody 5.24.2A03 within SEQ ID NO: 165 QSALTQPPSASGSPGQSVTISCTGTSSDVGVYNSVSWYRQHPGKVPKLMIYEVSKRPSG VPDRFSGSKSGNTASLTVSGLQADDEGDYYCCSCSGTNSLCVFGTGTKVTVL; CDR 1 (SEQ ID NO: 166) SSDVGVYNS; CDR2 (SEQ ID NO: 167) EVSK; and CDR3 (SEQ ID NO: 168) CSCSGTNSLCV; and

[0081] the three heavy chain CDRs of antibody 5.24.2A03 within SEQ ID NO:169 QVQLHESGPGLVQPSETLSLTCTVSGDSITNYYWSWIRQPPGKGLEWIGYMYYSASAHY NPSLQSRVTISVDTSKNQFSLKLSSVTAADTAVYFCARVDYSSSSYYSGNWFDPWGQGT LVTVSS; CDR 1 (SEQ ID NO: 170) GDSITNYY; CDR 2 (SEQ ID NO: 171) MYYSASA; and CDR 3 (SEQ ID NO: 172) ARVDYSSSSYYSGNWFDP.

[0082] In certain embodiments, the CDRs comprise

[0083] the three light chain CDRs of antibody 9.20.1A02 within SEQ ID NO: 173 QSVLTQPPSVSGAPGQTVTISCTGSYSNIGAGYDVQWYQHLPGTAPKLLIYDNVHRPSG VPDRFSGSKSGTSASLAITGLQTEDEADYYCQSYDSRLRDQWVFGGGTKLTVL; CDR 1 (SEQ ID NO: 174) YSNIGAGYD; CDR2 (SEQ ID NO: 175) DNVH; and CDR3 (SEQ ID NO: 176) QSYDSRLRDQWV; and

[0084] the three heavy chain CDRs of antibody 9.20.1A02 within SEQ ID NO: 177 EVQLVESGGDLVQPGGSLRLSCAASGITLSGVWMNWVRQAPGKGLEWIGRIKSTSDGG RADFAAPARGRFTMSRDESKNKLFLQMNNLGIEDTGMYYCFTRVQRDGTKDDFWGRG TLVTVSS; CDR 1 (SEQ ID NO: 178) GITLSGVW; CDR 2 (SEQ ID NO: 179) IKSTSDGGRA; and CDR 3 (SEQ ID NO: 180) FTRVQRDGTKDDF.

[0085] In certain embodiments, the CDRs comprise

[0086] the three light chain CDRs of antibody 5.24.2C05 within SEQ ID NO: 181 QSALTQPASVSGSPGQSITLSCTVGGNKFVSWYQQHPGKAPKLIISDFTDRPSGVSSRFSG SKSGNTASLTISGLQPDDEATYFCSSYASTSTSLWVFGGGTKLTVL; CDR 1 (SEQ ID NO: 182) CTVGGNKF; CDR2 (SEQ ID NO: 183) DFTD; and CDR3 (SEQ ID NO: 184) SSYASTSTSLWV; and

[0087] the three heavy chain CDRs of antibody 5.24.2C05 within SEQ ID NO: 185 QEQLQESGPGLVKPSGTLSLTCTVSGVSVSGSYFWNWVRQPPGKGLEWLGFIHSTGSTN TNPSLKSRVTISVDTSKNQFSLRLTSVSAADTAVYYCARAAWLVGGEYYNYGMDLWG QGTTVTVSS; CDR 1 (SEQ ID NO: 186) GVSVSGSYF; CDR 2 (SEQ ID NO: 187) IHSTGST; CDR 3 (SEQ ID NO: 188) ARAAWLVGGEYYNYGMDL.

[0088] In certain embodiments, the CDRs comprise

[0089] the three light chain CDRs of antibody 5.24.2B07 within SEQ ID NO: 189 GIQLTQSPSFLSASVGDRVTITCRASQGIYTYLAWYQQKPGKAPKLLVYVASTLQSGVPS RFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGQGTKLEIK; CDR 1 (SEQ ID NO: 190) QGIYTY; CDR2 (SEQ ID NO: 191) VAST; and CDR3 (SEQ ID NO: 192) QQLNSYPLT; and

[0090] the three heavy chain CDRs of antibody 5.24.2B07 within SEQ ID NO: 193 QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAFIWYDGTI QYYGDSVKGRFIISRDNSRNTLYLQMNSLRAEDTAVYYCASTLYRNGDYGSGSRTPDD YWGQGTLVTVSS; CDR 1 (SEQ ID NO: 194) GFTFSSYG; CDR 2 (SEQ ID NO: 195) IWYDGTIQ; and CDR 3 (SEQ ID NO: 196) ASTLYRNGDYGSGSRTPDDY.

[0091] In certain embodiments, an antibody or antigen binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 125, 133, 141, 149, 157, 165, 173, 181 or 189 having at least 80, 85, 90, 95, 98, 99%, or more sequence identity or similarity thereto.

[0092] In certain embodiments, an antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 129, 137, 145, 153, 161, 169, 177, 185, or 193 having at least 80, 85, 90, 95, 98, 99%, or more sequence identity or similarity thereto.

[0093] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 126, 127, 128, 130, 131, and 132, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0094] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 134, 135, 136, 138, 139, and 140, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0095] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 142, 143, 144, 146, 147, and 148, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0096] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 150, 151, 152, 154, 155, 156, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0097] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 158 159 160, 162, 163, 164, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0098] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 166, 167, 168, 170, 171, 172, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0099] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 174, 175, 176, 178, 179, 180 wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0100] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 182, 183, 184, 186, 187, 188, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0101] In certain embodiments, the antibody or antigen binding fragment has CDRs of SEQ ID NO: 190, 191, 192, 194, 195, 196, wherein one, two, three, four, five, or all of the CDRs contain one, two, three, or four amino acid substitutions. In certain embodiments, the substitutions are conservative substitutions.

[0102] In certain embodiments, the antibody, antigen binding fragment, the light chain, or the heavy chain comprises a non-naturally occurring chimeric amino acid sequence such that there is at least one mutation that is not present in naturally occurring antibodies comprising the six CDRs.

[0103] In certain embodiments, the antibody, antigen binding fragment, or heavy chain, comprises a human constant domain from an immunoglobulin constant region (Fc) having one, two, three, four, five, six, or more of the following mutations G236A, S239D, A330L, I332E, S267E, L328F, P238D, H268F, S324T, S228P, G236R, L328R, L234A, L235A, M252Y, S254T, T256E, M428L, N434S, A330L, N297A, N297Q.

[0104] In certain embodiments, this disclosure relates to antibodies comprising the triple mutation M252Y/S254T/T256E or the quadruple mutation of G236A/S239D/A330L/1332E.

[0105] In certain embodiments, antigen binding fragments disclosed herein comprises a human constant domain from an immunoglobulin constant region (Fc). In certain embodiments, the antibody or antigen fragment disclosed herein, comprising at least one amino acid substitution in the heavy chain constant region that is not present in naturally occurring antibodies comprising the six CDRs. In certain embodiments, the heavy chain comprises a sequence in a constant region that is different from any sequences present in naturally derived antibodies for which the light chain variable region comprise the three light chain CDRs and the heavy chain variable region comprise the three light chain CDRs or consensus sequences thereof.

[0106] In certain embodiments, the epitope expressed on an Ebola virus particle is arrayed on a surface, expressed on the surface of a cell, or expressed at an endogenous or transfected concentration, and the antibody or antigen binding fragment is bound to the epitope.

[0107] In certain embodiments, the antibody or antigen binding fragment is capable inducing an immune response to the Ebola virus or capable of neutralizing an of Ebola virus from replicating.

[0108] In certain embodiments, the disclosure relates to nucleic acids encoding an antibody or antigen binding fragment disclosed herein or a vector or expression system comprising such a nucleic acid. In certain embodiments, the disclosure relates to nucleic acids disclosed herein and variants which are synonymous mutations and non-synonymous mutations, e.g., codon optimized mutations.

[0109] In certain embodiments, the antibody or antigen binding fragment thereof is detectably labeled or comprises a conjugated toxin, drug, receptor, enzyme, receptor ligand.

[0110] In certain embodiments, the disclosure relates to pharmaceutical compositions comprising the antibody or antigen binding fragment thereof disclosed herein, and a physiologically acceptable carrier or excipient.

[0111] In certain embodiments, the disclosure relates to methods of detection Ebola virus infection, comprising: (a) assaying the expression of Ebola virus epitope in cells or in a tissue sample of a subject using the antibody or antigen binding fragment thereof disclosed herein and (b) comparing the level of the Ebola virus epitope with a control level, wherein an increase in the assayed level of Ebola virus compared to the control level is indicative of the infection.

[0112] In certain embodiments, the expression of Ebola virus epitope is assayed by enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), or fluorescence-activated cell sorting (FACS).

[0113] In certain embodiments, the disclosure relates to methods of preventing or treating an Ebola virus infection comprising administering an effective amount of a pharmaceutical composition disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with an Ebola virus infection.

BRIEF DESCRIPTION OF THE DRAWINGS

[0114] FIG. 1 illustrates a method of isolating variable antibody sequences from cells and grafting them to human constant regions.

[0115] FIG. 2 illustrates nucleic acid sequences encoding and amino acid sequences for the heavy (right) and light (left) variable regions of antibodies 5.1.10B3 and 5.6.1A02.

[0116] FIG. 3 illustrates nucleic acid sequences encoding and amino acid sequences for the heavy (right) and light (left) variable regions of antibodies 2.1.1D05 and 2.1.1D07.

[0117] FIG. 4 illustrates nucleic acid sequences encoding and amino acid sequences for the heavy (right) and light (left) variable regions of antibody 9.6.3D06.

[0118] FIG. 5 shows data on antibodies against maEVOV in BALB/c mice. Mice were given 100 ug of the indicated mAbs 24 hours prior to challenge with 100 pfu of Ebola Zaire (Mayinga strain). Note: C13C6 is a previously described antibody and component of Zmapp that was included as a control. 42-2D2 is an influenza specific negative control mAb made at Emory.

[0119] FIG. 6 shows data on antibodies. Mice were given 100 ug of the indicated mAbs 24 hours prior to challenge with 100 pfu of Ebola Zaire (Mayinga strain). Note: ATK-13 is the same as 5.6.c2618.

[0120] FIG. 7 shows data on antibodies against maEBOV in BALB/c Mice. Mice were given 100 ug of the indicated mAbs 24 hours prior to challenge with 100 pfu of Ebola Zaire (Mayinga strain). Note: C13C6 is a previously described antibody and component of Zmapp that was included as a control. 42-2D2 is an influenza specific negative control mAb made at Emory.

[0121] FIG. 8 illustrates nucleic acid sequences for the heavy (right) and light (left) variable regions of antibodies 2.1.1B02, 5.24.1C11 and 9.20.1CB3.

[0122] FIG. 9 illustrates nucleic acid sequences for the heavy (right) and light (left) variable regions of antibodies 5.24.1B3, 9.20.1D09 and 5.24.2A03.

[0123] FIG. 10 illustrates nucleic acid sequences for the heavy (right) and light (left) variable regions of antibodies 9.20.1A02, 5.24.2C05 and 5.24.2B07.

DETAILED DESCRIPTION

[0124] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

[0125] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.

[0126] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.

[0127] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.

[0128] Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of medicine, organic chemistry, biochemistry, molecular biology, pharmacology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.

[0129] In the claims appended hereto, the term "a" or "an" is intended to mean "one or more," and the term "comprise" and variations thereof such as "comprises" and "comprising," when preceding the recitation of a step or an element, are intended to mean that the addition of further steps or elements is optional and not excluded.

[0130] As used herein, the terms "treat," "treating," "treatment" and "therapeutic use" refer to the elimination, reduction or amelioration of one or more symptoms of a disease or disorder that would benefit from an increased or decreased immune response. As used herein, a "therapeutically effective amount" refers to that amount of a therapeutic agent sufficient to mediate an altered immune response, and more preferably, a clinically relevant altered immune response, sufficient to mediate a reduction or amelioration of a symptom. An effect is clinically relevant if its magnitude is sufficient to impact the health or prognosis of a recipient subject. A therapeutically effective amount refers to the amount of the therapeutic agent that provides a therapeutic benefit in the treatment.

[0131] The term "subject" can include, for example, domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.) mammals, non-human mammals, primates, non-human primates, rodents, birds, reptiles, amphibians, fish, and any other animal. The subject can be a mammal such as a primate or a human patient.

[0132] The term "sample" refers to any mixture of biological materials derived from a subject, e.g., bodily fluids, whole blood, serum, plasma, tissue, skin, saliva, urine, stool, tears, amniotic fluid, breast milk etc. Biological samples may be obtained from animals (including humans) and encompass fluids, solids, tissues, and gases.

[0133] As used herein, a molecule is said to be able to "immunospecifically bind" a second molecule if such binding exhibits the specificity and affinity of an antibody to its cognate antigen. Antibodies are said to be capable of "immunospecifically binding" to a target region or conformation ("epitope") of an antigen if such binding involves the antigen recognition site of the immunoglobulin molecule. An antibody that immunospecifically binds to a particular antigen may bind to other antigens with lower affinity if the other antigen has some sequence or conformational similarity that is recognized by the antigen recognition site as determined by, e.g., immunoassays, but would not bind to a totally unrelated antigen. Preferably, however, antibodies (and their antigen binding fragments) will not cross-react with other antigens. Antibodies may also bind to other molecules in a way that is not immunospecific, such as to FcR receptors, by virtue of binding domains in other regions/domains of the molecule that do not involve the antigen recognition site, such as the Fc region.

[0134] The term "substantially," as used in the context of binding or exhibited effect, is intended to denote that the observed effect is physiologically or therapeutically relevant. Thus, for example, a molecule is able to substantially block an activity of an Ebola virus if the extent of blockage is physiologically or therapeutically relevant (for example if such extent is greater than 60% complete, greater than 70% complete, greater than 75% complete, greater than 80% complete, greater than 85% complete, greater than 90% complete, greater than 95% complete, or greater than 97% complete). Similarly, a molecule is said to have substantially the same immunospecificity and/or characteristic as another molecule, if such immunospecificities and characteristics are greater than 60% identical, greater than 70% identical, greater than 75% identical, greater than 80% identical, greater than 85% identical, greater than 90% identical, greater than 95% identical, or greater than 97% identical).

[0135] The terms "vector" or "expression vector" refer to a recombinant nucleic acid containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism or expression system, e.g., cellular or cell-free. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.

[0136] Protein "expression systems" refer to in vivo and in vitro (cell free) systems. Systems for recombinant protein expression typically utilize cells transfecting with a DNA expression vector that contains the template. The cells are cultured under conditions such that they translate the desired protein. Expressed proteins are extracted for subsequent purification. In vivo protein expression systems using prokaryotic and eukaryotic cells are well known. Also, some proteins are recovered using denaturants and protein-refolding procedures. In vitro (cell-free) protein expression systems typically use translation-compatible extracts of whole cells or compositions that contain components sufficient for transcription, translation and optionally post-translational modifications such as RNA polymerase, regulatory protein factors, transcription factors, ribosomes, tRNA cofactors, amino acids and nucleotides. In the presence of an expression vectors, these extracts and components can synthesize proteins of interest. Cell-free systems typically do not contain proteases and enable labeling of the protein with modified amino acids. Some cell free systems incorporated encoded components for translation into the expression vector. See, e.g., Shimizu et al., Cell-free translation reconstituted with purified components, 2001, Nat. Biotechnol., 19, 751-755 and Asahara & Chong, Nucleic Acids Research, 2010, 38(13): e141, both hereby incorporated by reference in their entirety.

[0137] A "selectable marker" is a nucleic acid introduced into a recombinant vector that encodes a polypeptide that confers a trait suitable for artificial selection or identification (report gene), e.g., beta-lactamase confers antibiotic resistance, which allows an organism expressing beta-lactamase to survive in the presence antibiotic in a growth medium. Another example is thymidine kinase, which makes the host sensitive to ganciclovir selection. It may be a screenable marker that allows one to distinguish between wanted and unwanted cells based on the presence or absence of an expected color. For example, the lac-z-gene produces a beta-galactosidase enzyme which confers a blue color in the presence of X-gal (5-bromo-4-chloro-3-indolyl-.beta.-D-galactoside). If recombinant insertion inactivates the lac-z-gene, then the resulting colonies are colorless. There may be one or more selectable markers, e.g., an enzyme that can complement to the inability of an expression organism to synthesize a particular compound required for its growth (auxotrophic) and one able to convert a compound to another that is toxic for growth. URA3, an orotidine-5' phosphate decarboxylase, is necessary for uracil biosynthesis and can complement ura3 mutants that are auxotrophic for uracil. URA3 also converts 5-fluoroorotic acid into the toxic compound 5-fluorouracil. Additional contemplated selectable markers include any genes that impart antibacterial resistance or express a fluorescent protein. Examples include, but are not limited to, the following genes: ampr, camr, tetr, blasticidinr, neor, hygr, abxr, neomycin phosphotransferase type II gene (nptII), p-glucuronidase (gus), green fluorescent protein (gfp), egfp, yfp, mCherry, p-galactosidase (lacZ), lacZa, lacZAM15, chloramphenicol acetyltransferase (cat), alkaline phosphatase (phoA), bacterial luciferase (luxAB), bialaphos resistance gene (bar), phosphomannose isomerase (pmi), xylose isomerase (xylA), arabitol dehydrogenase (atlD), UDP-glucose:galactose-1-phosphate uridyltransferasel (galT), feedback-insensitive .alpha. subunit of anthranilate synthase (OASA1D), 2-deoxyglucose (2-DOGR), benzyladenine-N-3-glucuronide, E. coli threonine deaminase, glutamate 1-semialdehyde aminotransferase (GSA-AT), D-amino acidoxidase (DAAO), salt-tolerance gene (rstB), ferredoxin-like protein (pflp), trehalose-6-P synthase gene (AtTPS1), lysine racemase (lyr), dihydrodipicolinate synthase (dapA), tryptophan synthase beta 1 (AtTSB1), dehalogenase (dhlA), mannose-6-phosphate reductase gene (M6PR), hygromycin phosphotransferase (HPT), and D-serine ammonialyase (dsdA).

[0138] A "label" refers to a detectable compound or composition that is conjugated directly or indirectly to another molecule, such as an antibody or a protein, to facilitate detection of that molecule. Specific, non-limiting examples of labels include fluorescent tags, enzymatic linkages, and radioactive isotopes. In one example, a "label receptor" refers to incorporation of a heterologous polypeptide in the receptor. A label includes the incorporation of a radiolabeled amino acid or the covalent attachment of biotinyl moieties to a polypeptide that can be detected by marked avidin (for example, streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). Various methods of labeling polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionucleotides (such as 35S or 131I) fluorescent labels (such as fluorescein isothiocyanate (FITC), rhodamine, lanthanide phosphors), enzymatic labels (such as horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase), chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (such as a leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), or magnetic agents, such as gadolinium chelates. In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

[0139] In certain embodiments, the disclosure relates to antibodies and antigen binding fragments comprising sequences disclosed herein or variants or fusions thereof wherein the amino terminal end or the carbon terminal end of the amino acid sequence are optionally attached to a heterologous amino acid sequence, label, or reporter molecule.

[0140] In certain embodiments, the disclosure relates to vectors comprising a nucleic acid encoding an antibody or antigen binding fragment disclosed herein or chimeric protein thereof.

[0141] In certain embodiments, the vector optionally comprises a mammalian, human, insect, viral, bacterial, bacterial plasmid, yeast associated origin of replication or gene such as a gene or retroviral gene or lentiviral LTR, TAR, RRE, PE, SLIP, CRS, and INS nucleotide segment or gene selected from tat, rev, nef, vif, vpr, vpu, and vpx or structural genes selected from gag, pol, and env.

[0142] In certain embodiments, the vector optionally comprises a gene vector element (nucleic acid) such as a selectable marker region, lac operon, a CMV promoter, a hybrid chicken B-actin/CMV enhancer (CAG) promoter, tac promoter, T7 RNA polymerase promoter, SP6 RNA polymerase promoter, SV40 promoter, internal ribosome entry site (IRES) sequence, cis-acting woodchuck post regulatory regulatory element (WPRE), scaffold-attachment region (SAR), inverted terminal repeats (ITR), FLAG tag coding region, c-myc tag coding region, metal affinity tag coding region, streptavidin binding peptide tag coding region, polyHis tag coding region, HA tag coding region, MBP tag coding region, GST tag coding region, polyadenylation coding region, SV40 polyadenylation signal, SV40 origin of replication, Col E1 origin of replication, f1 origin, pBR322 origin, or pUC origin, TEV protease recognition site, loxP site, Cre recombinase coding region, or a multiple cloning site such as having 5, 6, or 7 or more restriction sites within a continuous segment of less than 50 or 60 nucleotides or having 3 or 4 or more restriction sites with a continuous segment of less than 20 or 30 nucleotides.

[0143] In certain embodiments, term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.

[0144] In certain embodiments, sequence "identity" refers to the number of exactly matching amino acids (expressed as a percentage) in a sequence alignment between two sequences of the alignment calculated using the number of identical positions divided by the greater of the shortest sequence or the number of equivalent positions excluding overhangs wherein internal gaps are counted as an equivalent position. For example the polypeptides GGGGGG and GGGGT have a sequence identity of 4 out of 5 or 80%. For example, the polypeptides GGGPPP and GGGAPPP have a sequence identity of 6 out of 7 or 85%. In certain embodiments, any recitation of sequence identity expressed herein may be substituted for sequence similarity. Percent "similarity" is used to quantify the similarity between two sequences of the alignment. This method is identical to determining the identity except that certain amino acids do not have to be identical to have a match. Amino acids are classified as matches if they are among a group with similar properties according to the following amino acid groups: Aromatic--F Y W; hydrophobic-A V I L; Charged positive: R K H; Charged negative--D E; Polar--S T N Q.

[0145] As used herein, the term "combination with" when used to describe administration with an additional treatment means that the agent may be administered prior to, together with, or after the additional treatment, or a combination thereof.

Ebola Virus

[0146] Ebola is a deadly disease caused by infection with one of the Ebola virus species. The disease is spread through direct contact with bodily fluids, contaminated objects, infected fruit bats or primates, or from sexual contact. In a period from 3-21 days, Ebola virus causes symptoms such as fever, muscle pain, and vomiting, and can also lead to unexplained hemorrhage and, if left untreated, eventually death. Although it is considered a rare disease, in 2014, the largest Ebola outbreak in history nucleated in West Africa (Guinea) and was thought to be caused by a new Ebola virus strain.

[0147] Ebola viruses are categorized in the family Filoviridae and typically cause severe hemorrhagic fevers and fatalities in humans. Ebola viruses include Zaire Ebola virus (EBOV), Sudan virus (SUDV), Tai forest virus (TAFV), Bundibugyo virus (BDBV), and Reston virus (RESTV). The Ebolavirus virion core consists of the negative-sense RNA genome. The core is surrounded by a lipid envelope with surface projections that are comprised of a glycoprotein (GP). Ebola viruses are RNA viruses that are thread-like in appearance and consist of seven structural proteins including glycoprotein, matrix proteins, and nucleocapsid proteins. Virus particles are surrounded by a host cell-derived membrane in which the surface glycoprotein GP is embedded.

[0148] Typically survival from an Ebola viral infection depends on access to adequate healthcare early in disease progression. Treatment consists of providing fluids, maintaining oxygen and blood pressure, and treating other infections. Survivors do develop antibodies against Ebola virus that may persist for up to 10 years.

[0149] Ebola virus infections typically result in with onset of fever and chills, but low-grade fever and malaise may also precede the development of more severe symptoms. Watery diarrhea nausea, vomiting, and abdominal pain are common. Gastrointestinal bleeding, blood in the stool, and mucosal bleeding may occur. Blurred vision, photophobia, blindness may occur during the acute phase of illness. A diffuse erythematous, nonpruritic maculopapular rash may develop. The rash usually involves the face, neck, trunk, and arms, and can desquamate. Multi-organ failure with death typically occurring in the second week.

[0150] The presence of the Ebola virus can be done by the detection of viral RNA, e.g. by RT-PCR, and/or by detection of Ebola antigen by a specific Antigen detection test, and/or by detection of immunoglobulin M (IgM) antibodies directed against Ebola.

Antibody and Antigen Binding Fragments

[0151] As used herein, the term "antibody" is intended to denote an immunoglobulin molecule that possesses a "variable region" antigen recognition site. The term "variable region" is intended to distinguish such domain of the immunoglobulin from domains that are broadly shared by antibodies (such as an antibody Fc domain). The variable region comprises a "hypervariable region" whose residues are responsible for antigen binding. The hypervariable region comprises amino acid residues from a "Complementarity Determining Region" or "CDR" (i.e., typically at approximately residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and at approximately residues 27-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) and/or those residues from a "hypervariable loop" (i.e., residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917). "Framework Region" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined. The term antibody includes monoclonal antibodies, multi-specific antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, camelized antibodies (See e.g., Muyldermans et al., 2001, Trends Biochem. Sci. 26:230; Nuttall et al., 2000, Cur. Pharm. Biotech. 1:253; Reichmann and Muyldermans, 1999, J. Immunol. Meth. 231:25; International Publication Nos. WO 94/04678 and WO 94/25591; U.S. Pat. No. 6,005,079), single-chain Fvs (scFv) (see, e.g., see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994)), single chain antibodies, disulfide-linked Fvs (sdFv), intrabodies, and anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id and anti-anti-Id antibodies to the disclosed B7-H5 antibodies). In particular, such antibodies include immunoglobulin molecules of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.

[0152] As used herein, the term "antigen binding fragment" of an antibody refers to one or more portions of an antibody that contain the antibody's Complementarity Determining Regions ("CDRs") and optionally the framework residues that comprise the antibody's "variable region" antigen recognition site, and exhibit an ability to immunospecifically bind an antigen. Such fragments include Fab', F(ab')2, Fv, single chain (ScFv), and mutants thereof, naturally occurring variants, and fusion proteins comprising the antibody's "variable region" antigen recognition site and a heterologous protein (e.g., a toxin, an antigen recognition site for a different antigen, an enzyme, a receptor or receptor ligand, etc.). As used herein, the term "fragment" refers to a peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least 200 contiguous amino acid residues, or at least 250 contiguous amino acid residues.

[0153] Human, non-naturally occurring chimeric or humanized derivatives of anti-Ebola virus antibodies are particularly preferred for in vivo use in humans, however, murine antibodies or antibodies of other species may be advantageously employed for many uses (for example, in vitro or in situ detection assays, acute in vivo use, etc.). A humanized antibody may comprises amino acid residue substitutions, deletions or additions in one or more non-human CDRs. The humanized antibody derivative may have substantially the same binding, stronger binding or weaker binding when compared to a non-derivative humanized antibody. In specific embodiments, one, two, three, four, or five amino acid residues of the CDR have been substituted, deleted or added (i.e., mutated). Completely human antibodies are particularly desirable for therapeutic treatment of human subjects.

[0154] Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences (see U.S. Pat. Nos. 4,444,887 and 4,716,111; and International Publication Nos. WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741). Human antibodies can be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized using conventional methodologies with a selected antigen, e.g., all or a portion of an Ebola virus polypeptide.

[0155] Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology (see, e.g., U.S. Pat. No. 5,916,771). The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995, Int. Rev. Immunol. 13:65-93, which is incorporated herein by reference in its entirety). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., International Publication Nos. WO 98/24893, WO 96/34096, and WO 96/33735; and U.S. Pat. Nos. 5,413,923, 5,625,126, 5,633,425, 5,569,825, 5,661,016, 5,545,806, 5,814,318, and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, Calif.) and Medarex (Princeton, N.J.) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

[0156] A "chimeric antibody" is a molecule in which different portions of the antibody are derived from different immunoglobulin molecules such that the entire molecule is not naturally occurring. Examples of chimeric antibodies include those having a variable region derived from a non-human antibody and a human immunoglobulin constant region. The term is also intended to include antibodies having a variable region derived from one human antibody grafted to an immunoglobulin constant region of a predetermined sequences or the constant region from another human for which there are allotypic differences residing in the constant regions of any naturally occurring antibody having the variable regions, e.g., CDRs 1, 2, and 3 of the light and heavy chain. Human heavy chain genes exhibit structural polymorphism (allotypes) that are inherited as a haplotype. The serologically defined allotypes differ within and between population groups. See Jefferis et al. mAb, 1 (2009), pp. 332-338.

[0157] Smith et al. report a protocol for the production of antigen-specific chimeric human monoclonal antibodies (hmAbs) wherein antibody-secreting cells (ASCs) are isolated from whole blood collected after vaccination and sorted by flow cytometry into single cell plates. Nat Protoc. 2009; 4(3):372-84. The antibody genes of the ASCs are then amplified by RT-PCR and nested PCR, cloned into expression vectors and transfected into a human cell line. Meijer et al. report methods for isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J Mol Biol. 2006 May 5; 358(3):764-72. Wrammert et al. report using immunoglobulin variable regions isolated from sorted single ASCs to produce human monoclonal antibodies (mAbs) that bound with high affinity. Nature. 2008 May 29; 453(7195): 667-671.

[0158] Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, 1985, Science 229:1202; Oi et al., 1986, BioTechniques 4:214; Gillies et al., 1989, J. Immunol. Methods 125:191-202; and U.S. Pat. Nos. 6,311,415, 5,807,715, 4,816,567, and 4,816,397. Chimeric antibodies comprising one or more CDRs from a non-human species and framework regions from a human immunoglobulin molecule can be produced using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; International Publication No. WO 91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering 7:805; and Roguska et al., 1994, Proc. Natl. Acad. Sci. USA 91:969), and chain shuffling (U.S. Pat. No. 5,565,332).

[0159] As used herein, the term "humanized antibody" refers to an immunoglobulin comprising a human framework region and one or more CDR's from a non-human (usually a mouse or rat) immunoglobulin. The non-human immunoglobulin providing the CDR's is called the "donor" and the human immunoglobulin providing the framework is called the "acceptor." Constant regions need not be present, but if they are, they must be substantially identical to human immunoglobulin constant regions, i.e., at least about 85-90%, preferably about 95% or more identical. Hence, all parts of a humanized immunoglobulin, except possibly the CDR's, are substantially identical to corresponding parts of natural human immunoglobulin sequences. A humanized antibody is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. For example, a humanized antibody would not encompass a typical chimeric antibody, because, e.g., the entire variable region of a chimeric antibody is non-human. One says that the donor antibody has been "humanized," by the process of "humanization," because the resultant humanized antibody is expected to bind to the same antigen as the donor antibody that provides the CDR's. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or a non-human primate having the desired specificity, affinity, and capacity. In some instances, Framework Region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin that immunospecifically binds to an Fc RIIB polypeptide, that has been altered by the introduction of amino acid residue substitutions, deletions or additions (i.e., mutations).

[0160] DNA sequences coding for preferred human acceptor framework sequences include but are not limited to FR segments from the human germline VH segment VH1-18 and JH6 and the human germline VL segment VK-A26 and JK4. In a specific embodiment, one or more of the CDRs are inserted within framework regions using routine recombinant DNA techniques. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., 1998, "Structural Determinants In the Sequences of Immunoglobulin Variable Domain," J. Mol. Biol. 278: 457-479 for a listing of human framework regions).

[0161] A humanized or non-naturally occurring chimeric Ebola virus antibody can include substantially all of at least one, and typically two, variable domains in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e., donor antibody) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. Preferably, an Ebola virus antibody also includes at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. The constant domains of the Ebola virus antibodies may be selected with respect to the proposed function of the antibody, in particular the effector function which may be required. In some embodiments, the constant domains of the Ebola virus antibodies are (or comprise) human IgA, IgD, IgE, IgG or IgM domains. In a specific embodiment, human IgG constant domains, especially of the IgG1 and IgG3 isotypes are used, when the humanized Ebola virus antibodies is intended for therapeutic uses and antibody effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity are needed. In alternative embodiments, IgG2 and IgG4 isotypes are used when the Ebola virus antibody is intended for therapeutic purposes and antibody effector function is not required. The disclosure encompasses Fc constant domains comprising one or more amino acid modifications which alter antibody effector functions such as those disclosed in U.S. Patent Application Publication Nos. 2005/0037000 and 2005/0064514.

[0162] In some embodiments, the Ebola virus antibody contains both the light chain as well as at least the variable domain of a heavy chain. In other embodiments, the Ebola virus antibody may further include one or more of the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain. The antibody can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgG1, IgG2, IgG3 and IgG4. In some embodiments, the constant domain is a complement fixing constant domain where it is desired that the antibody exhibit cytotoxic activity, and the class is typically IgG1. In other embodiments, where such cytotoxic activity is not desirable, the constant domain may be of the IgG2 class. The Ebola virus antibody may comprise sequences from more than one class or isotype, and selecting particular constant domains to optimize desired effector functions is within the ordinary skill in the art.

[0163] The framework and CDR regions of a humanized antibody need not correspond precisely to the parental sequences, e.g., the donor CDR or the consensus framework may be mutagenized by substitution, insertion or deletion of at least one residue so that the CDR or framework residue at that site does not correspond to either the consensus or the donor antibody. Such mutations, however, are preferably not extensive. Usually, at least 75% of the humanized antibody residues will correspond to those of the parental framework region (FR) and CDR sequences, more often 90%, and most preferably greater than 95%. Humanized antibodies can be produced using variety of techniques known in the art, including, but not limited to, CDR-grafting (European Patent No. EP 239,400; International Publication No. WO 91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (European Patent Nos. EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering 7(6):805-814; and Roguska et al., 1994, Proc. Natl. Acad. Sci. 91:969-973), chain shuffling (U.S. Pat. No. 5,565,332), and techniques disclosed in, e.g., U.S. Pat. Nos. 6,407,213, 5,766,886, 5,585,089, International Publication No. WO 9317105, Tan et al., 2002, J. Immunol. 169:1119-25, Caldas et al., 2000, Protein Eng. 13:353-60, Morea et al., 2000, Methods 20:267-79, Baca et al., 1997, J. Biol. Chem. 272:10678-84, Roguska et al., 1996, Protein Eng. 9:895-904, Couto et al., 1995, Cancer Res. 55 (23 Supp):5973s-5977s, Couto et al., 1995, Cancer Res. 55:1717-22, Sandhu, 1994, Gene 150:409-10, Pedersen et al., 1994, J. Mol. Biol. 235:959-73, Jones et al., 1986, Nature 321:522-525, Riechmann et al., 1988, Nature 332:323, and Presta, 1992, Curr. Op. Struct. Biol. 2:593-596. Often, framework residues in the framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; U.S. Publication Nos. 2004/0049014 and 2003/0229208; U.S. Pat. Nos. 6,350,861; 6,180,370; 5,693,762; 5,693,761; 5,585,089; and 5,530,101 and Riechmann et al., 1988, Nature 332:323).

[0164] The antibodies used in the methods of the present disclosure may be monospecific. Also of interest are bispecific antibodies, trispecific antibodies or antibodies of greater multispecificity that exhibit specificity to different targets in the Ebola virus.

[0165] The antibodies of the present disclosure may be produced by any method known in the art useful for the production of polypeptides, e.g., in vitro synthesis, recombinant DNA production, and the like. Preferably, the antibodies are produced by recombinant DNA technology. The Ebola virus antibodies may be produced using recombinant immunoglobulin expression technology. The recombinant production of immunoglobulin molecules, including humanized antibodies are described in U.S. Pat. No. 4,816,397 (Boss et al.), U.S. Pat. Nos. 6,331,415 and 4,816,567 (both to Cabilly et al.), U.K. patent GB 2,188,638 (Winter et al.), and U.K. patent GB 2,209,757. Techniques for the recombinant expression of immunoglobulins, including humanized immunoglobulins, can also be found, in Goeddel et al., Gene Expression Technology Methods in Enzymology Vol. 185 Academic Press (1991), and Borreback, Antibody Engineering, W. H. Freeman (1992). Additional information concerning the generation, design and expression of recombinant antibodies can be found in Mayforth, Designing Antibodies, Academic Press, San Diego (1993).

[0166] Host cells may be co-transfected with such expression vectors, which may contain different selectable markers but, with the exception of the heavy and light chain coding sequences, are preferably identical. This procedure provides for equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes both heavy and light chain polypeptides. The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA or both. The host cell used to express the recombinant Ebola virus antibody can be either a bacterial cell such as Escherichia coli, or more preferably a eukaryotic cell (e.g., a Chinese hamster ovary (CHO) cell or a HEK-293 cell). The choice of expression vector is dependent upon the choice of host cell, and may be selected so as to have the desired expression and regulatory characteristics in the selected host cell. Other cell lines that may be used include, but are not limited to, CHO-K1, NSO, and PER.C6 (Crucell, Leiden, Netherlands).

[0167] Any of the antibodies disclosed herein can be used to generate antiidiotype antibodies using techniques well known to those skilled in the art (see, e.g., Greenspan, N. S. et al. (1989) "Idiotypes: Structure and Immunogenicity," FASEB J. 7:437-444; and Nisinoff, A. (1991) "Idiotypes: Concepts and Applications," J. Immunol. 147(8):2429-2438).

[0168] The binding properties of any of the above antibodies can, if desired, be further improved by screening for variants that exhibit such desired characteristics. For example, such antibodies can be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains, such as Fab and Fv or disulfide-bond stabilized Fv, expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage, including fd and M13. The antigen binding domains are expressed as a recombinantly fused protein to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the immunoglobulins, or fragments thereof, of the present disclosure include those disclosed in Brinkman, U. et al. (1995) "Phage Display Of Disulfide-Stabilized Fv Fragments," J. Immunol. Methods, 182:41-50, 1995; Ames, R. S. et al. (1995) "Conversion Of Murine Fabs Isolated From A Combinatorial Phage Display Library To Full Length Immunoglobulins," J. Immunol. Methods, 184:177-186; Kettleborough, C. A. et al. (1994) "Isolation Of Tumor Cell-Specific Single-Chain Fv From Immunized Mice Using Phage-Antibody Libraries And The Re-Construction Of Whole Antibodies From These Antibody Fragments," Eur. J. Immunol., 24:952-958, 1994; Persic, L. et al. (1997) "An Integrated Vector System For The Eukaryotic Expression Of Antibodies Or Their Fragments After Selection From Phage Display Libraries," Gene, 187:9-18; Burton, D. R. et al. (1994) "Human Antibodies From Combinatorial Libraries," Adv. Immunol. 57:191-280; PCT Publications WO 92/001047; WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108.

[0169] As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including humanized antibodies, or any other desired fragments, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')2 fragments can also be employed using methods known in the art (such as those disclosed in PCT Publication WO 92/22324; Mullinax, R. L. et al. (1992) "Expression Of A Heterodimeric Fab Antibody Protein In One Cloning Step," BioTechniques, 12(6):864-869; and Sawai et al. (1995) "Direct Production Of The Fab Fragment Derived From The Sperm Immobilizing Antibody Using Polymerase Chain Reaction And cDNA Expression Vectors," Am. J. Reprod. Immunol. 34:26-34; and Better, M. et al. (1988) "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," Science 240:1041-1043). Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Pat. Nos. 4,946,778 and 5,258,498; Huston, J. S. et al. (1991) "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins," Methods in Enzymology 203:46-88; Shu, L. et al., "Secretion of a Single-Gene-Encoded Immunoglobulin from Myeloma Cells," Proc. Natl. Acad. Sci. (USA) 90:7995-7999; and Skerra. A. et al. (1988) "Assembly of a Functional Immunoglobulin Fv Fragment in Escherichia coli," Science 240:1038-1040.

[0170] Phage display technology can be used to increase the affinity of an antibody for Ebola virus. This technique would be useful in obtaining high affinity antibodies that could be used in the disclosed combinatorial methods. This technology, referred to as affinity maturation, employs mutagenesis or CDR walking and re-selection using such receptors or ligands (or their extracellular domains) or an antigenic fragment thereof to identify antibodies that bind with higher affinity to the antigen when compared with the initial or parental antibody (See, e.g., Glaser, S. M. et al. (1992) "Antibody Engineering by Codon-Based Mutagenesis in a Filamentous Phage Vector System," J. Immunol. 149:3903-3913). Mutagenizing entire codons rather than single nucleotides results in a semi-randomized repertoire of amino acid mutations. Libraries can be constructed consisting of a pool of variant clones each of which differs by a single amino acid alteration in a single CDR and which contain variants representing each possible amino acid substitution for each CDR residue. Mutants with increased binding affinity for the antigen can be screened by contacting the immobilized mutants with labeled antigen. Any screening method known in the art can be used to identify mutant antibodies with increased avidity to the antigen (e.g., ELISA) (see, e.g., Wu, H. et al. (1998) "Stepwise In Vitro Affinity Maturation Of Vitaxin, An Alphav Beta3-Specific Humanized Mab," Proc. Natl. Acad. Sci. (USA) 95(11):6037-6042; Yelton, D. E. et al. (1995) "Affinity Maturation Of The BR96 Anti-Carcinoma Antibody By Codon-Based Mutagenesis," J. Immunol. 155:1994-2004). CDR walking which randomizes the light chain may be used possible (see, Schier et al. (1996) "Isolation Of Picomolar Affinity Anti-C-Erbb-2 Single-Chain Fv By Molecular Evolution Of The Complementarity Determining Regions In The Center Of The Antibody Binding Site," J. Mol. Biol. 263:551-567).

[0171] The disclosure contemplates the use of random mutagenesis to identify improved CDRs. Phage display technology can alternatively be used to increase (or decrease) CDR affinity. This technology, referred to as affinity maturation, employs mutagenesis or "CDR walking" and re-selection uses the target antigen or an antigenic fragment thereof to identify antibodies having CDRs that bind with higher (or lower) affinity to the antigen when compared with the initial or parental antibody (see, e.g., Glaser, S. M. et al. (1992) "Antibody Engineering By Codon-Based Mutagenesis In A Filamentous Phage Vector System," J. Immunol. 149:3903-3913). Mutagenizing entire codons rather than single nucleotides results in a semi-randomized repertoire of amino acid mutations. Libraries can be constructed consisting of a pool of variant clones each of which differs by a single amino acid alteration in a single CDR and which contain variants representing each possible amino acid substitution for each CDR residue. Mutants with increased (or decreased) binding affinity for the antigen can be screened by contacting the immobilized mutants with labeled antigen. Any screening method known in the art can be used to identify mutant antibodies with increased (or decreased) avidity to the antigen (e.g., ELISA) (see, Wu, H. et al. (1998) "Stepwise In Vitro Affinity Maturation Of Vitaxin, An Alphav Beta3-Specific Humanized Mab," Proc. Natl. Acad. Sci. (USA) 95(11):6037-6042; Yelton, D. E. et al. (1995) "Affinity Maturation Of The BR96 Anti-Carcinoma Antibody By Codon-Based Mutagenesis," J. Immunol. 155:1994-2004). CDR walking which randomizes the light chain may be used possible (see, Schier et al. (1996) "Isolation Of Picomolar Affinity Anti-C-Erbb-2 Single-Chain Fv By Molecular Evolution Of The Complementarity Determining Regions In The Center Of The Antibody Binding Site," J. Mol. Biol. 263:551-567).

[0172] Methods for accomplishing such affinity maturation are described for example in: Krause, J. C. et al. (2011) "An Insertion Mutation that Distorts Antibody Binding Site Architecture Enhances Function of a Human Antibody," MBio. 2(1) pii: e00345-10. doi: 10.1128/mBio.00345-10; Kuan, C. T. et al. (2010) "Affinity-Matured Anti-Glycoprotein NMB Recombinant Immunotoxins Targeting Malignant Gliomas and Melanomas," Int. J. Cancer 10.1002/ijc.25645; Hackel, B. J. et al. (2010) "Stability and CDR Composition Biases Enrich Binder Functionality Landscapes," J. Mol. Biol. 401(1):84-96; Montgomery, D. L. et al. (2009) "Affinity Maturation and Characterization of a Human Monoclonal Antibody Against HIV-1 gp41," MAbs 1(5):462-474; Gustchina, E. et al. (2009) "Affinity Maturation By Targeted Diversification of the CDR-H2 Loop of a Monoclonal Fab Derived From A Synthetic Naive Human Antibody Library And Directed Against The Internal Trimeric Coiled-Coil Of Gp41 Yields A Set Of Fabs With Improved HIV-1 Neutralization Potency And Breadth," Virology 393(1):112-119; Finlay, W. J. et al. (2009) "Affinity Maturation of a Humanized Rat Antibody ror Anti-RAGE Therapy: Comprehensive Mutagenesis Reveals a High Level of Mutational Plasticity Both Inside and Outside the Complementarity-Determining Regions," J. Mol. Biol. 388(3):541-558; Bostrom, J. et al. (2009) "Improving Antibody Binding Affinity and Specificity for Therapeutic Development," Methods Mol. Biol. 525:353-376; Steidl, S. et al. (2008) "In Vitro Affinity Maturation of Human GM-CSF Antibodies by Targeted CDR-Diversification," Mol. Immunol. 46(1):135-144; and Barderas, R. et al. (2008) "Affinity Maturation of Antibodies Assisted by in Silico Modeling," Proc. Natl. Acad. Sci. (USA) 105(26):9029-9034.

[0173] In certain embodiments, the antibody, antigen binding fragment, the light chain, or the heavy chain comprises a non-naturally occurring chimeric amino acid sequence such that there is at least one mutation that is not present in naturally occurring antibodies comprising the six CDRs. In certain embodiments, the antibody, antigen binding fragment, or heavy chain, comprises a human constant domain from an immunoglobulin constant region (Fc) having one, two, three, four, five, six, or more of the following mutations G236A, S239D, A330L, I332E, S267E, L328F, P238D, H268F, S324T, S228P, G236R, L328R, L234A, L235A, M252Y, S254T, T256E, M428L, N434S. With regard to IgG-1 Fc mutations reported herein the sequences are in reference to following amino acid sequence (SEQ ID NO: 50) starting at amino acid 119:

TABLE-US-00001 STKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 178 GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG 238 PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNAKTKPREEQYN 298 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE 358 LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 418 QQGNVFSCSV MHEALHNHYT QKSLSLSPG.

[0174] In certain embodiments, In certain embodiments, this disclosure relates to antibodies reported wherein the constant region comprises a mutation that activates immune responses such as those selected from the constant region comprises as least one, two, three, or more mutations in the Fc domain selected from S239D, I332E, G236A, A330L, or combinations thereof.

[0175] FcgRIIb has immunosuppressive function. In certain embodiments, this disclosure relates to antibodies reported wherein the constant region comprises a mutation that suppressed immune responses those selected from the constant region comprises as least one, two, three, or more mutations in the Fc domain selected from S267E, L328F, P238D, or combinations thereof.

[0176] Antibodies interact with the complement cascade through C1q binding enabling antibodies to activate complement-dependent cytotoxicity (CDC). In certain embodiments, this disclosure relates to antibodies reported wherein the constant region comprises a mutation that effectively active complement-dependent cytotoxicity such as those selected from S267E, H268F, S324T, and combinations thereof.

[0177] In certain embodiment interaction with the immune system through Fc receptors may be unnecessary or undesirable, i.e., immune-silent antibodies. In certain embodiments, this disclosure relates to antibodies reported wherein the constant region comprises a mutation that bind the antigen but do not bind to FcgRs such as those selected from S228P, G236R, L328R, L234A, L235A, or combinations thereof.

[0178] In certain embodiments, is may be desirable to have antibodies wherein constant region of the Fc has been to increase or decrease antibody half-life. In certain embodiments, this disclosure relates to antibodies reported wherein the constant region comprises a mutation that increases or decreases the antibodies half-life such as those selected from M252Y, S254T, T256E, M428L, N434S or combinations thereof.

[0179] The disclosure particularly contemplates the production and use of "derivatives" of any of the above-described antibodies and their antigen-binding fragments. The term "derivative" refers to an antibody or antigen-binding fragment thereof that immunospecifically binds to an antigen but which comprises, one, two, three, four, five or more amino acid substitutions, additions, deletions or modifications relative to a "parental" (or wild-type) molecule. Such amino acid substitutions or additions may introduce naturally occurring (i.e., DNA-encoded) or non-naturally occurring amino acid residues. The term "derivative" encompasses, for example, chimeric or humanized variants of any of antibodies, as well as variants having altered CH1, hinge, CH2, CH3 or CH4 regions, so as to form, for example antibodies, etc., having variant Fc regions that exhibit enhanced or impaired effector or binding characteristics.

[0180] The term "derivative" additionally encompasses non-amino acid modifications, for example, amino acids that may be glycosylated (e.g., have altered mannose, 2-N-acetylglucosamine, galactose, fucose, glucose, sialic acid, 5-N-acetylneuraminic acid, 5-glycolneuraminic acid, etc. content), acetylated, pegylated, phosphorylated, amidated, derivatized by known protecting/blocking groups, proteolytic cleavage, linked to a cellular ligand or other protein, etc. In some embodiments, the altered carbohydrate modifications modulate one or more of the following: solubilization of the antibody, facilitation of subcellular transport and secretion of the antibody, promotion of antibody assembly, conformational integrity, and antibody-mediated effector function. In a specific embodiment the altered carbohydrate modifications enhance antibody mediated effector function relative to the antibody lacking the carbohydrate modification. Carbohydrate modifications that lead to altered antibody mediated effector function are well known in the art (for example, see Shields, R. L. et al. (2002) "Lack of Fucose on Human IgG N-Linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-Dependent Cellular Toxicity," J. Biol. Chem. 277(30): 26733-26740; Davies J. et al. (2001) "Expression of GnTIII in a Recombinant Anti-CD20 CHO Production Cell Line: Expression of Antibodies with Altered Glycoforms Leads to an Increase In ADCC Through Higher Affinity For FC Gamma RIII," Biotechnology & Bioengineering 74(4): 288-294). Methods of altering carbohydrate contents are known to those skilled in the art, see, e.g., Wallick, S. C. et al. (1988) "Glycosylation of a VH Residue of a Monoclonal Antibody Against Alpha (1-6) Dextran Increases its Affinity for Antigen," J. Exp. Med. 168(3): 1099-1109; Tao, M. H. et al. (1989) "Studies of Aglycosylated Chimeric Mouse-Human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," J. Immunol. 143(8): 2595-2601; Routledge, E. G. et al. (1995) "The Effect of Aglycosylation on the Immunogenicity of a Humanized Therapeutic CD3 Monoclonal Antibody," Transplantation 60(8):847-53; Elliott, S. et al. (2003) "Enhancement of Therapeutic Protein in Vivo Activities Through Glycoengineering," Nature Biotechnol. 21:414-21; Shields, R. L. et al. (2002) "Lack of Fucose on Human IgG N-Linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-Dependent Cellular Toxicity," J. Biol. Chem. 277(30): 26733-26740).

[0181] In some embodiments, a humanized antibody is a derivative. Such a humanized antibody comprises amino acid residue substitutions, deletions or additions in one or more CDRs. The humanized antibody derivative may have substantially the same binding, better binding, or worse binding when compared to a non-derivative humanized antibody. In specific embodiments, one, two, three, four, or five amino acid residues of the CDR have been substituted, deleted or added (i.e., mutated).

[0182] A derivative antibody or antibody fragment may be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, etc. In one embodiment, an antibody derivative will possess a similar or identical function as the parental antibody. In another embodiment, an antibody derivative will exhibit an altered activity relative to the parental antibody. For example, a derivative antibody (or fragment thereof) can bind to its epitope more tightly or be more resistant to proteolysis than the parental antibody.

[0183] Derivatized antibodies may be used to alter the half-lives (e.g., serum half-lives) of parental antibodies in a mammal, preferably a human. Preferably such alteration will result in a half-life of greater than 15 days, preferably greater than 20 days, greater than 25 days, greater than 30 days, greater than 35 days, greater than 40 days, greater than 45 days, greater than 2 months, greater than 3 months, greater than 4 months, or greater than 5 months. The increased half-lives of the humanized antibodies of the present disclosure or fragments thereof in a mammal, preferably a human, results in a higher serum titer of said antibodies or antibody fragments in the mammal, and thus, reduces the frequency of the administration of said antibodies or antibody fragments and/or reduces the concentration of said antibodies or antibody fragments to be administered. Antibodies or fragments thereof having increased in vivo half-lives can be generated by techniques known to those of skill in the art. For example, antibodies or fragments thereof with increased in vivo half-lives can be generated by modifying (e.g., substituting, deleting or adding) amino acid residues identified as involved in the interaction between the Fc domain and the FcRn receptor. The Ebola virus antibodies can be engineered to increase biological half-lives (see, e.g. U.S. Pat. No. 6,277,375). For example, Ebola virus antibodies can be engineered in the Fc-hinge domain to have increased in vivo or serum half-lives.

[0184] Antibodies or fragments thereof with increased in vivo half-lives can be generated by attaching to said antibodies or antibody fragments polymer molecules such as high molecular weight polyethyleneglycol (PEG). PEG can be attached to said antibodies or antibody fragments with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C-terminus of said antibodies or antibody fragments or via epsilon-amino groups present on lysine residues. Linear or branched polymer derivatization that results in minimal loss of biological activity will be used. The degree of conjugation will be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the antibodies. Unreacted PEG can be separated from antibody-PEG conjugates by, e.g., size exclusion or ion-exchange chromatography.

[0185] The Ebola virus antibodies may also be modified by the methods and coupling agents described by Davis et al. (See U.S. Pat. No. 4,179,337) in order to provide compositions that can be injected into the mammalian circulatory system with substantially no immunogenic response.

[0186] One embodiment encompasses modification of framework residues of the Ebola virus antibodies. Framework residues in the framework regions may be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., U.S. Pat. No. 5,585,089; and Riechmann, L. et al. (1988) "Reshaping Human Antibodies for Therapy," Nature 332:323-327).

[0187] Yet another embodiment encompasses Ebola virus antibodies (and more preferably, humanized antibodies) and antigen-binding fragments thereof that are recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a heterologous molecule (i.e., an unrelated molecule). The fusion does not necessarily need to be direct, but may occur through linker sequences.

[0188] In one embodiment such heterologous molecules are polypeptides having at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino acids. Such heterologous molecules may alternatively be enzymes, hormones, cell surface receptors, drug moieties, such as: toxins (such as abrin, ricin A, pseudomonas exotoxin (i.e., PE-40), diphtheria toxin, ricin, gelonin, or pokeweed antiviral protein), proteins (such as tumor necrosis factor, interferon (e.g., alpha-interferon, beta-interferon), nerve growth factor, platelet derived growth factor, tissue plasminogen activator, or an apoptotic agent (e.g., tumor necrosis factor-alpha, tumor necrosis factor-bet.)), biological response modifiers (such as, for example, a lymphokine (e.g., interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6")), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or macrophage colony stimulating factor, ("M-CSF")), or growth factors (e.g., growth hormone ("GH"))), cytotoxins (e.g., a cytostatic or cytocidal agent, such as paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof), antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, BiCNU.RTM. (carmustine; BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cisdichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), or anti-mitotic agents (e.g., vincristine and vinblastine).

[0189] Techniques for conjugating such therapeutic moieties to antibodies are well known; see, e.g., Arnon et al., "Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy", in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Reisfeld et al. (eds.), 1985, pp. 243-56, Alan R. Liss, Inc.); Hellstrom et al., "Antibodies for Drug Delivery", in CONTROLLED DRUG DELIVERY (2nd Ed.), Robinson et al. (eds.), 1987, pp. 623-53, Marcel Dekker, Inc.); Thorpe, "Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review", in MONOCLONAL ANTIBODIES '84: BIOLOGICAL AND CLINICAL APPLICATIONS, Pinchera et al. (eds.), 1985, pp. 475-506); "Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy", in MONOCLONAL ANTIBODIES FOR CANCER DETECTION AND THERAPY, Baldwin et al. (eds.), 1985, pp. 303-16, Academic Press; and Thorpe et al. (1982) "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates," Immunol. Rev. 62:119-158.

[0190] In one embodiment, the Ebola virus antibodies or Ebola virus fusion molecules include an Fc portion. The Fc portion of such molecules may be varied by isotype or subclass, may be a chimeric or hybrid, and/or may be modified, for example to improve effector functions, control of half-life, tissue accessibility, augment biophysical characteristics such as stability, and improve efficiency of production (and less costly). Many modifications useful in construction of disclosed fusion proteins and methods for making them are known in the art, see for example Mueller, J. P. et al. (1997) "Humanized Porcine VCAM-Specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," Mol. Immun 34(6):441-452, Swann, P. G. (2008) "Considerations for the Development of Therapeutic Monoclonal Antibodies," Curr. Opin. Immun. 20:493-499 (2008), and Presta, L. G. (2008) "Molecular Engineering and Design of Therapeutic Antibodies," Curr. Opin. Immun 20:460-470. In some embodiments, the Fc region is the native IgG1, IgG2, or IgG4 Fc region. In some embodiments, the Fc region is a hybrid, for example a chimeric consisting of IgG2/IgG4 Fc constant regions. Modifications to the Fc region include, but are not limited to, IgG4 modified to prevent binding to Fc gamma receptors and complement, IgG1 modified to improve binding to one or more Fc gamma receptors, IgG1 modified to minimize effector function (amino acid changes), IgG1 with altered/no glycan (typically by changing expression host), and IgG1 with altered pH-dependent binding to FcRn, and IgG4 with serine at amino acid resident #228 in the hinge region changed to proline (S228P) to enhance stability. The Fc region may include the entire hinge region, or less than the entire hinge region.

[0191] Another embodiment includes IgG2-4 hybrids and IgG4 mutants that have reduced binding to FcR which increase their half-life. Representative IG2-4 hybrids and IgG4 mutants are described in Angal, S. et al. (1993) "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," Molec. Immunol. 30(1):105-108; Mueller, J. P. et al. (1997) "Humanized Porcine VCAM-Specific Monoclonal Antibodies With Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding To Porcine Endothelial Cells," Mol. Immun 34(6):441-452; and U.S. Pat. No. 6,982,323. In some embodiments the IgG1 and/or IgG2 domain is deleted for example, Angal, s. et al. describe IgG1 and IgG2 having serine 241 replaced with a proline.

[0192] In a preferred embodiment, the Fc domain contains amino acid insertions, deletions or substitutions that enhance binding to CD16A. A large number of substitutions in the Fc domain of human IgG1 that increase binding to CD16A and reduce binding to CD32B are known in the art and are described in Stavenhagen, et al., Cancer Res., 57(18):8882-90 (2007). Exemplary variants of human IgG1 Fc domains with reduced binding to CD32B and/or increased binding to CD16A contain F243L, R929P, Y300L, V3051 or P296L substitutions. These amino acid substitutions may be present in a human IgG1 Fc domain in any combination. In one embodiment, the human IgG1 Fc domain variant contains a F243L, R929P and Y300L substitution. In another embodiment, the human IgG1 Fc domain variant contains a F243L, R929P, Y300L, V3051 and P296L substitution. In another embodiment, the human IgG1 Fc domain variant contains an N297Q substitution, as this mutation abolishes FcR binding.

[0193] Substitutions, additions or deletions in the derivatized antibodies may be in the Fc region of the antibody and may thereby serve to modify the binding affinity of the antibody to one or more Fc R. Methods for modifying antibodies with modified binding to one or more Fc R are known in the art, see, e.g., PCT Publication Nos. WO 04/029207, WO 04/029092, WO 04/028564, WO 99/58572, WO 99/51642, WO 98/23289, WO 89/07142, WO 88/07089, and U.S. Pat. Nos. 5,843,597 and 5,642,821. In one particular embodiment, the modification of the Fc region results in an antibody with an altered antibody-mediated effector function, an altered binding to other Fc receptors (e.g., Fc activation receptors), an altered antibody-dependent cell-mediated cytotoxicity (ADCC) activity, an altered C1q binding activity, an altered complement-dependent cytotoxicity activity (CDC), a phagocytic activity, or any combination thereof.

[0194] In some embodiments, the disclosure encompasses antibodies whose Fc region will have been modified so that the molecule will exhibit altered Fc receptor (FcR) binding activity, for example to exhibit decreased activity toward activating receptors such as FcgammaRIIA or FcgammaRIIIA, or increased activity toward inhibitory receptors such as FcgammaRIIB Preferably, such antibodies will exhibit decreased antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) activities (relative to a wild-type Fc receptor).

[0195] Modifications that affect Fc-mediated effector function are well known in the art (see U.S. Pat. No. 6,194,551, and WO 00/42072; Stavenhagen, J. B. et al. (2007) "Fc Optimization Of Therapeutic Antibodies Enhances Their Ability To Kill Tumor Cells In Vitro And Controls Tumor Expansion In Vivo Via Low-Affinity Activating Fcgamma Receptors," Cancer Res. 57(18):8882-8890; Shields, R. L. et al. (2001) "High Resolution Mapping of the Binding Site on Human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc.gamma.R," J. Biol. Chem. 276(9):6591-6604). Exemplary variants of human IgG1 Fc domains with reduced binding to FcgammaRIIA or FcgammaRIIIA, but unchanged or enhanced binding to FcgammaRIIB, include S239A, H268A, S267G, E269A, E293A, E293D, Y296F, R301A, V303A, A327G, K322A, E333A, K334A, K338A, A339A, D376A.

[0196] In some embodiments, the disclosure encompasses antibodies whose Fc region will have been deleted (for example, an Fab or F(ab).sub.2, etc.).

[0197] Any of the molecules of the present disclosure can be fused to marker sequences, such as a peptide, to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, the hemagglutinin "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I. A. et al. (1984) "The Structure Of An Antigenic Determinant In A Protein," Cell, 37:767-778) and the "flag" tag (Knappik, A. et al. (1994) "An Improved Affinity Tag Based On The FLAG Peptide For The Detection And Purification Of Recombinant Antibody Fragments," Biotechniques 17(4):754-761).

[0198] In some embodiments, the antigen binding fragments may comprise one, two, or more of the CDRs or variable regions, e.g., a light chain variable region having a flexible linker such as a polyglycine, linked to the heavy chain variable region which is further fused to a polypeptide having a signal-transduction component of a T-cell antigen receptor domain, e.g., constant Fc domain or CD3-zeta. In certain embodiments, the signal-transduction component of the T-cell antigen receptor is a peptide with an immunoreceptor tyrosine-based activation motif with the consensus sequence YXXL(X)nYXXL (SEQ ID NO: 61) wherein X is any amino acid L is leucine or isoleucine, wherein n is 6, 7, or 8. For example, the immunoreceptor tyrosine-based activation motif (underlined) is in the partial CD3-zeta sequences:

[0199] AQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSADAPAYQQGQN QLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 62) or AQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSADAPAYQQGQNQLYN ELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMK GERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 63) or AQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSAEPPAYQQGQNQLYNE LNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE RRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 64) or fragments or variants, e.g. having 1, 2, or 3 amino acid deletion, addition, or substitution variants, or a sequence with greater than 50, 60, 70, 80, 90, 95% or greater identity thereto.

[0200] In certain embodiments, the signal-transduction component of the T-cell antigen receptor is a peptide with a immunoreceptor tyrosine-based activation motif (underlined) with the sequence of immunoglobulin epsilon receptor subunit gamma precursor EPQLCYILDAILFLYGIVLTLLYCRLKIQVRKAAITSYEKSDGVYTGLSTRNQETYETLK HE (SEQ ID NO: 65) fragments or variants thereof variants or a sequence with greater than 50, 60, 70, 80, 90, 95% or greater identity thereto.

[0201] The present disclosure also encompasses antibodies or their antigen-binding fragments that are conjugated to a diagnostic or therapeutic agent or any other molecule for which serum half-life is desired to be increased. The antibodies can be used diagnostically (in vivo, in situ or in vitro) to, for example, monitor the development or progression of a disease, disorder or infection as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present disclosure.

[0202] Such diagnosis and detection can be accomplished by coupling the antibody to detectable substances including, but not limited to, various enzymes, enzymes including, but not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; prosthetic group complexes such as, but not limited to, streptavidin/biotin and avidin/biotin; fluorescent materials such as, but not limited to, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; luminescent material such as, but not limited to, luminol; bioluminescent materials such as, but not limited to, luciferase, luciferin, and aequorin; radioactive material such as, but not limited to, bismuth (.sup.213Bi), carbon (.sup.14C), chromium (.sup.51Cr), cobalt (.sup.57Co), fluorine (.sup.18F), gadolinium (.sup.153Gd, .sup.159Gd), gallium (.sup.68Ga, .sup.67Ga), germanium (.sup.68Ge), holmium (.sup.166Ho), indium (.sup.115In, .sup.113In, .sup.112In, iodine (.sup.131I, .sup.125I, .sup.123I, .sup.121I), lanthanium (.sup.140La), lutetium (.sup.177Lu), manganese (.sup.54Mn), molybdenum (.sup.99Mo), palladium (103Pd), phosphorous (.sup.32P), praseodymium (.sup.142Pr), promethium, (.sup.149Pm), rhenium (.sup.186Re, .sup.188Re), rhodium (.sup.105Rh), ruthenium (.sup.97Ru), samarium (.sup.153Sm), scandium (.sup.47Sc), selenium (.sup.75Se), strontium (.sup.85Sr), sulfur (.sup.35S), technetium (.sup.99Tc), thallium (.sup.201Ti), tin (.sup.113Sn, .sup.117Sn), tritium (.sup.3H), xenon (.sup.133Xe), ytterbium (.sup.169YB, .sup.175Yb) yttrium (.sup.90Y), zinc (.sup.65Zn); positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions.

[0203] The molecules of the present disclosure can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Pat. No. 4,676,980. Such heteroconjugate antibodies may additionally bind to haptens (such as fluorescein, etc.), or to cellular markers (e.g., PD-1, 4-1-BB, B7-H4, B7-H5, CD4, CD8, CD14, CD25, CD27, CD28, CD40, CD68, CD163, CTLA4, GITR, LAG-3, OX40, TIM3, TIM4, TLR2, LIGHT, etc.) or to cytokines (e.g., IL-7, IL-15, IL-12, IL-4 TGF-beta, IL-10, IL-17, IFNg, Flt3, BLys) or chemokines (e.g., CCL21), etc.

[0204] The molecules of the present disclosure may be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen or of other molecules that are capable of binding to target antigen that has been immobilized to the support via binding to an antibody or antigen-binding fragment of the present disclosure. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

[0205] The present disclosure additionally includes nucleic acid molecules (DNA or RNA) that encode any such antibodies, fusion proteins or fragments, as well as vector molecules (such as plasmids) that are capable of transmitting or of replication such nucleic acid molecules and expressing such antibodies, fusion proteins or fragments in a cell line. The nucleic acids can be single-stranded, double-stranded, may contain both single-stranded and double-stranded portions.

Consensus Sequences

[0206] In certain embodiments, the disclosure relates to antibodies or fragments comprising six CDRs having consensus sequences.

[0207] Light chain CDR is of antibodies disclosed herein:

TABLE-US-00002 CDR 1 SEQ ID NO: 11) RASQSISSFLN, CDR 1 (SEQ ID NO: 17) RSSQSLLHRNGYNYLD, CDR 1 (SEQ ID NO: 29) RASQSVSSSYLA, CDR 1 (SEQ ID NO: 35) RASQRINNLVA.

[0208] Consensus sequences for light chain CDR 1:

[0209] CDR 1 (SEQ ID NO: 41) RX.sup.1SQXIX.sup.2, wherein X.sup.1 is A, S, or any amino acid and X.sup.2 is S, R, or any amino acid and

[0210] CDR 1 (SEQ ID NO: 42) RX.sup.1SQSX.sup.2, wherein X.sup.1 is A, S, or any amino acid and X.sup.2 is I, L, V, or any amino acid.

[0211] Light chain CDR 2s of antibodies disclosed herein:

TABLE-US-00003 CDR 2 (SEQ ID NO: 12) AASSLQS, CDR 2 (SEQ ID NO: 36) DASSLKS, CDR 2 (SEQ ID NO: 18) LGSNRAS, CDR 2 (SEQ ID NO: 24) GNSNRPS, CDR 2 (SEQ ID NO: 30) GAFNRAT.

[0212] Consensus sequences for light chain CDR 2s:

[0213] CDR 2 (SEQ ID NO: 43) ASSLX.sup.1S, wherein X.sup.1 is a Q, K, or any amino acid and

[0214] CDR 2 (SEQ ID NO: 44) X.sup.1SNRX.sup.2S, wherein X.sup.1 is G, L, or any amino acid, and X is A, P, or any amino acid.

[0215] Light chain CDR 3s of antibodies disclosed herein:

TABLE-US-00004 CDR3 (SEQ ID NO: 13) Q Q S Y I S P F T, CDR3 (SEQ ID NO: 31) Q L Y G S S P W T, CDR 3 (SEQ ID NO: 37) Q Q Y D T D S G W T.

[0216] Consensus sequences for light chain CDR 3s:

[0217] CDR 3 (SEQ ID NO: 45) QX.sup.1X.sup.2X.sup.3X.sup.4SPX.sup.5T, wherein X.sup.1 is Q, L, Y or any amino acid, X.sup.2 is S, Y, D or any amino acid, X.sup.3 is Y, G, T or any amino acid, X.sup.4 is I, S, D or any amino acid, and X.sup.5 is F, W or any amino acid.

[0218] Heavy Chain CDR is of antibodies disclosed herein:

TABLE-US-00005 CDR 1 (SEQ ID NO: 14) FTFRSYDMH, CDR 1 (SEQ ID NO: 20) FAVRSNYLS, CDR 1 (SEQ ID NO: 26) FTFSNAWMN, CDR 1 (SEQ ID NO: 32) FTFSTYGMS, CDR 1 (SEQ ID NO: 38) FTFSKYAMI.

[0219] Consensus sequences for heavy chain CDR 1:

[0220] CDR 1 (SEQ ID NO: 46)

[0221] FX.sup.1X.sup.2RSX.sup.3 wherein X.sup.1 is T, A, or any amino acid, X.sup.2 is F, V, or any amino acid, and X.sup.3 is Y, N, A or any amino acid and

[0222] CDR 1 (SEQ ID NO: 47)

[0223] FTFX.sup.1X.sup.2YX.sup.3M, wherein X1 is R, S, or any amino acid, X2 is S, N, T, K, or any amino acid, X3 D, Y, W, G, A, or any amino acid.

[0224] Heavy Chain CDR 2s of antibodies disclosed herein:

TABLE-US-00006 CDR 2 (SEQ ID NO: 15) I G T A G D T Y Y P G S V K G, CDR 2 (SEQ ID NO: 21) L I Y S G G L T A Y A D S V E G, CDR 2 (SEQ ID NO: 27) R I K S K T D G G A A D Y A A P V K G, CDR 2 (SEQ ID NO: 33) G I S G S G G I T Y Y A D S V R G, CDR 2 (SEQ ID NO: 39) G I N K S G G R T Y Y A D S V R G.

[0225] Consensus sequences for heavy chain CDR 2:

[0226] CDR 2 (SEQ ID NO: 48)

[0227] GX.sup.1X.sup.2X.sup.3YX.sup.4X.sup.5SVX.sup.6G, wherein X.sup.1 is D, L, A, I, R, or any amino acid, X.sup.2 is T, A, or any amino acid, X.sup.3 is Y, A, D, or any amino acid, X.sup.4 is P, A, or any amino acid, X.sup.5 is K, E, R, or any amino acid and

[0228] Heavy Chain CDR 3s of antibodies disclosed herein:

TABLE-US-00007 CDR3 (SEQ ID NO: 16) V R F G D T A V D Y and CDR3 (SEQ ID NO: 22) V A S S A G T F Y Y G M D V.

[0229] Consensus sequences for heavy chain CDR 3:

TABLE-US-00008 CDR 3 (SEQ ID NO: 49) VX.sup.1X.sup.2X.sup.3X.sup.4X.sup.5X.sup.6X.sup.7X.sup.8Y

[0230] Wherein X.sup.1 is R, A, or any amino acid, X.sup.2 is F, S or any amino acid, X.sup.3 is G, S, or any amino acid, X.sup.4 is D, A, or any amino acid, X.sup.5 is T, G, or any amino acid, X.sup.6 is A, T, or any amino acid, X.sup.7 is V, F, or any amino acid, X.sup.8 is D, Y, or any amino acid.

[0231] In certain embodiments, the disclosure relates to antibodies or fragments comprising six CDRs having the consensus sequences. With regard to the consensus sequences any of the amino acid positions may be desirable to substitute an amino acid that corresponds to the sequence in any antibody disclosed herein.

[0232] In certain embodiments, the disclosure relates to antibodies or fragments wherein the light chain comprises

[0233] a) a light chain CDR 1 selected from

[0234] CDR 1 (SEQ ID NO: 41) RX.sup.1SQXIX.sup.2, wherein X.sup.1 is A, S, or any amino acid and X.sup.2 is S, R, or any amino acid and

[0235] CDR 1 (SEQ ID NO: 42) RX.sup.1SQSX.sup.2, wherein X.sup.1 is A, S, or any amino acid and X.sup.2 is I, L, V, or any amino acid;

[0236] b) a light chain CDR 2 selected from:

[0237] CDR 2 (SEQ ID NO: 43) ASSLX.sup.1S, wherein X.sup.1 is a Q, K, or any amino acid and CDR 2 (SEQ ID NO: 44) X.sup.1SNRX.sup.2S, wherein X.sup.1 is G, L, or any amino acid, and X is A, P, or any amino acid; and

[0238] c) a light chain CDR 3 comprising (SEQ ID NO: 45) QX.sup.1X.sup.2X.sup.3X.sup.4SPX.sup.5T, wherein X.sup.1 is Q, L, Y or any amino acid, X.sup.2 is S, Y, D or any amino acid, X.sup.3 is Y, G, T or any amino acid, X.sup.4 is I, S, D or any amino acid, and X.sup.5 is F, W or any amino acid.

[0239] In certain embodiments, the disclosure relates to antibodies or fragments wherein the heavy chain comprises,

[0240] a) a heavy chain CDR 1 selected from (SEQ ID NO: 46) FX.sup.1X.sup.2RSX.sup.3 wherein X.sup.1 is T, A, or any amino acid, X.sup.2 is F, V, or any amino acid, and X.sup.3 is Y, N, A or any amino acid and CDR 1 (SEQ ID NO: 47) FTFX.sup.1X.sup.2YX.sup.3M, wherein X1 is R, S, or any amino acid, X2 is S, N, T, K, or any amino acid, X3 D, Y, W, G, A, or any amino acid;

[0241] b) a heavy chain CDR 2 having (SEQ ID NO: 48) GX.sup.1X.sup.2X.sup.3YX.sup.4X.sup.5SVX.sup.6G, wherein X.sup.1 is D, L, A, I, R, or any amino acid, X.sup.2 is T, A, or any amino acid, X.sup.3 is Y, A, D, or any amino acid, X.sup.4 is P, A, or any amino acid, X.sup.5 is K, E, R, or any amino acid; and

[0242] c) a heavy chain CDR 3 having (SEQ ID NO: 49) VX.sup.1X.sup.2X.sup.3X.sup.4X.sup.5X.sup.6X.sup.7X.sup.8Y, wherein X.sup.1 is R, A, or any amino acid, X.sup.2 is F, S or any amino acid, X.sup.3 is G, S, or any amino acid, X.sup.4 is D, A, or any amino acid, X.sup.5 is T, G, or any amino acid, X.sup.6 is A, T, or any amino acid, X.sup.7 is V, F, or any amino acid, X.sup.8 is D, Y, or any amino acid.

[0243] In certain embodiments, the disclosure relates to antibodies or fragments wherein the light chain comprises

[0244] a CDR 1 having CDR 1 (SEQ ID NO: 41) RX.sup.1SQXIX.sup.2, wherein X.sup.1 is A, S, or any amino acid and X.sup.2 is S, R, or any amino acid,

[0245] a CDR 2 having CDR 2 (SEQ ID NO: 43) ASSLX'S, wherein X.sup.1 is a Q, K, or any amino acid, and

[0246] a CDR 3 (SEQ ID NO: 45) QX.sup.1X.sup.2X.sup.3X.sup.4SPX.sup.5T, wherein X.sup.1 is Q, L, Y or any amino acid, X.sup.2 is S, Y, D or any amino acid, X.sup.3 is Y, G, T or any amino acid, X.sup.4 is I, S, D or any amino acid, and X.sup.5 is F, W or any amino acid, and

[0247] the heavy chain comprises

[0248] a CDR 1 (SEQ ID NO: 46)

[0249] FX.sup.1X.sup.2RSX.sup.3 wherein X.sup.1 is T, A, or any amino acid, X.sup.2 is F, V, or any amino acid, and X.sup.3 is Y, N, A or any amino acid,

[0250] a CDR 2 (SEQ ID NO: 48)

[0251] GX.sup.1X.sup.2X.sup.3YX.sup.4X.sup.5SVX.sup.6G, wherein X.sup.1 is D, L, A, I, R, or any amino acid, X.sup.2 is T, A, or any amino acid, X.sup.3 is Y, A, D, or any amino acid, X.sup.4 is P, A, or any amino acid, X.sup.5 is K, E, R, or any amino acid; and

[0252] a CDR 3 (SEQ ID NO: 49)

[0253] VX.sup.1X.sup.2X.sup.3X.sup.4X.sup.5X.sup.6X.sup.7X.sup.8Y, wherein X.sup.1 is R, A, or any amino acid, X.sup.2 is F, S or any amino acid, X.sup.3 is G, S, or any amino acid, X.sup.4 is D, A, or any amino acid, X.sup.5 is T, G, or any amino acid, X.sup.6 is A, T, or any amino acid, X.sup.7 is V, F, or any amino acid, X.sup.8 is D, Y, or any amino acid.

Therapeutic Methods

[0254] In certain embodiments, the disclosure relates to methods of preventing or treating an Ebola virus infection comprising administering an effective amount of a pharmaceutical composition comprising an antibody or antigen binding fragment disclosed herein to a subject in need thereof. Treatment of a subject with a therapeutically or prophylactically effective amount of antibody or antibody binding fragment can include a single treatment or, preferably, can include a series of treatments. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with an Ebola virus infection.

[0255] In certain embodiments, the antibody or antigen binding fragment is administered in combination with another or second therapeutic agent or antiviral agent. In certain embodiments, the antiviral agent(s) is abacavir, acyclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, boceprevir, cidofovir, combivir, complera, darunavir, delavirdine, didanosine, docosanol, dolutegravir, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type III, interferon type II, interferon type I, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, oseltamivir, peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, stavudine, stribild, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir, or zidovudine, and combinations thereof.

[0256] In certain embodiments, the other or second therapeutic agent may be monoclonal antibodies (mabs) targeting the Ebola virus surface glycoprotein (GP) such as ZMAb (MAbs 2G4, 4G7, and 1H3) or MB-003 (MAbs 13C6, 6D8, and 13F6) or human chimera thereof. See Zeitlin et al., Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. U.S.A. 108, 20690-20694 (2011). The original murine 13F6 variable regions were deimmunized and were subsequently chimerized with human constant regions, containing an alanine at N297 of the human IgG1 heavy-chain constant region (h-13F6agly) to eliminate Fc glycosylation entirely. In certain embodiments, the disclosure contemplates that N297 may be substituted to any other nucleic acid such as G, A, S T, C, V, L, I, M, F, Y, P, W, D, E, H, K, or R. Other contemplated agents include interfering RNA (siRNA) or antisense oligonucleotides molecules, e.g., phosphorodiamidate morpholino oligomers (PMOs), that target Ebola mRNA.

[0257] The dosage amounts and frequencies of administration provided herein are encompassed by the terms therapeutically effective and prophylactically effective. The dosage and frequency further will typically vary according to factors specific for each patient depending on the specific therapeutic or prophylactic agents administered, the severity, the route of administration, as well as age, body weight, response, and the past medical history of the patient. Suitable regimens can be selected by one skilled in the art by considering such factors and by following, for example, dosages reported in the literature and recommended in the Physician's Desk Reference (56th Ed., 2002).

[0258] Various delivery systems are known and can be used to administer the therapeutic or prophylactic compositions, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the antibody or fusion protein, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a nucleic acid as part of a retroviral or other vector, etc.

[0259] Methods of administering antibodies and antigen binding fragments include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural, and mucosal (e.g., intranasal and oral routes). In a specific embodiment, the antibodies or fusion proteins are administered intramuscularly, intravenously, or subcutaneously. The compositions may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968; 5,985, 20; 5,985,309; 5,934,272; 5,874,064; 5,855,913; 5,290,540; and 4,880,078; and PCT Publication Nos. WO 92/19244; WO 97/32572; WO 97/44013; WO 98/31346; and WO 99/66903. In a specific embodiment, it may be desirable to administer the pharmaceutical compositions locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion, by injection, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

[0260] In some embodiments, the antibodies or antigen binding fragments are formulated in liposomes for targeted delivery of the antibodies or fusion proteins. Liposomes are vesicles comprised of concentrically ordered phospholipid bilayers which encapsulate an aqueous phase. Liposomes typically comprise various types of lipids, phospholipids, and/or surfactants. The components of liposomes are arranged in a bilayer configuration, similar to the lipid arrangement of biological membranes. Liposomes are particularly preferred delivery vehicles due, in part, to their biocompatibility, low immunogenicity, and low toxicity. Methods for preparation of liposomes are known in the art and are encompassed within the invention, see, e.g., Epstein et al., 1985, Proc. Natl. Acad. Sci. USA, 82: 3688; Hwang et al., 1980 Proc. Natl. Acad. Sci. USA, 77: 4030-4; U.S. Pat. Nos. 4,485,045 and 4,544,545.

[0261] Methods of preparing liposomes with a prolonged serum half-life, i.e., enhanced circulation time, such as those disclosed in U.S. Pat. No. 5,013,556 can be used to make liposomes-antibody compositions. Preferred liposomes are not rapidly cleared from circulation, i.e., are not taken up into the mononuclear phagocyte system (MPS). The invention encompasses sterically stabilized liposomes which are prepared using common methods known to one skilled in the art. Although not intending to be bound by a particular mechanism of action, sterically stabilized liposomes contain lipid components with bulky and highly flexible hydrophilic moieties, which reduces the unwanted reaction of liposomes with serum proteins, reduces opsonization with serum components and reduces recognition by MPS. Sterically stabilized liposomes are preferably prepared using polyethylene glycol. For preparation of liposomes and sterically stabilized liposome, see, e.g., Bendas et al., 2001 BioDrugs, 15(4): 215-224; Allen et al., 1987 FEBS Lett. 223: 42-6; Klibanov et al., 1990 FEBS Lett., 268: 235-7; Blum et al., 1990, Biochim. Biophys. Acta., 1029: 91-7; Torchilin et al., 1996, J. Liposome Res. 6: 99-116; Litzinger et al., 1994, Biochim. Biophys. Acta, 1190: 99-107; Maruyama et al., 1991, Chem. Pharm. Bull., 39: 1620-2; Klibanov et al., 1991, Biochim Biophys Acta, 1062; 142-8; Allen et al., 1994, Adv. Drug Deliv. Rev, 13: 285-309. The invention also encompasses liposomes that are adapted for specific organ targeting, see, e.g., U.S. Pat. No. 4,544,545, or specific cell targeting, see, e.g., U.S. Patent Application Publication No. 2005/0074403. Particularly useful liposomes for use in the disclosed compositions and methods can be generated by reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. In some embodiments, a fragment of an antibody, e.g., F(ab'), may be conjugated to the liposomes using previously described methods, see, e.g., Martin et al., 1982, J. Biol. Chem. 257: 286-288.

[0262] The antibodies, or antigen binding fragments may also be formulated as immunoliposomes. Immunoliposomes refer to a liposomal composition, wherein an antibody or a fragment thereof is linked, covalently or non-covalently to the liposomal surface. The chemistry of linking an antibody to the liposomal surface is known in the art and encompassed within the invention, see, e.g., U.S. Pat. No. 6,787,153; Allen et al., 1995, Stealth Liposomes, Boca Rotan: CRC Press, 233-44; Hansen et al., 1995, Biochim. Biophys. Acta, 1239: 133-144. In most preferred embodiments, immunoliposomes for use in the disclosed methods and compositions are further sterically stabilized. Preferably, the antibodies or antigen binding fragments are linked covalently or non-covalently to a hydrophobic anchor, which is stably rooted in the lipid bilayer of the liposome. Examples of hydrophobic anchors include, but are not limited to, phospholipids, e.g., phosoatidylethanolamine (PE), phosphatidylinositol (PI). To achieve a covalent linkage between an antibody and a hydrophobic anchor, any of the known biochemical strategies in the art may be used, see, e.g., J. Thomas August, ed., 1997, Gene Therapy: Advances in Pharmacology, Volume 40, Academic Press, San Diego, Calif., p. 399-435. For example, a functional group on an antibody molecule may react with an active group on a liposome associated hydrophobic anchor, e.g., an amino group of a lysine side chain on an antibody may be coupled to liposome associated N-glutaryl-phosphatidylethanolamine activated with water-soluble carbodiimide; or a thiol group of a reduced antibody can be coupled to liposomes via thiol reactive anchors, such as pyridylthiopropionylphosphatidylethanolamine. See, e.g., Dietrich et al., 1996, Biochemistry, 35: 1100-1105; Loughrey et al., 1987, Biochim. Biophys. Acta, 901: 157-160; Martin et al., 1982, J. Biol. Chem. 257: 286-288; Martin et al., 1981, Biochemistry, 20: 4429-38. Although not intending to be bound by a particular mechanism of action, immunoliposomal formulations including an antibody or fusion protein are particularly effective as therapeutic agents, since they deliver the antibody or fusion protein to the cytoplasm of the target cell, i.e., the cell comprising the receptor to which the antibody or fusion protein binds. The immunoliposomes preferably have an increased half-life in blood, specifically target cells, and can be internalized into the cytoplasm of the target cells thereby avoiding loss of the therapeutic agent or degradation by the endolysosomal pathway.

[0263] The immunoliposomal compositions include one or more vesicle forming lipids, an antibody or a fragment or derivative thereof or a fusion protein, and, optionally, a hydrophilic polymer. A vesicle forming lipid is preferably a lipid with two hydrocarbon chains, such as acyl chains and a polar head group. Examples of vesicle forming lipids include phospholipids, e.g., phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylinositol, sphingomyelin, and glycolipids, e.g., cerebrosides, gangliosides. Additional lipids useful in the formulations are known to one skilled in the art and encompassed within the invention. In some embodiments, the immunoliposomal compositions further comprise a hydrophilic polymer, e.g., polyethylene glycol, and ganglioside GM1, which increases the serum half-life of the liposome. Methods of conjugating hydrophilic polymers to liposomes are well known in the art and encompassed within the invention. For a review of immunoliposomes and methods of preparing them, see, e.g., U.S. Patent Application Publication No. 2003/0044407; PCT International Publication No. WO 97/38731, Vingerhoeads et al., 1994, Immunomethods, 4: 259-72; Maruyama, 2000, Biol. Pharm. Bull. 23(7): 791-799; Abra et al., 2002, Journal of Liposome Research, 12(1&2): 1-3; Park, 2002, Bioscience Reports, 22(2): 267-281; Bendas et al., 2001 BioDrugs, 14(4): 215-224, J. Thomas August, ed., 1997, Gene Therapy: Advances in Pharmacology, Volume 40, Academic Press, San Diego, Calif., p. 399-435.

[0264] The antibodies and antigen binding fragments can be packaged in a hermetically sealed container, such as an ampoule or sachette, indicating the quantity of antibody. In one embodiment, the antibodies are supplied as a dry sterilized lyophilized powder or water free concentrate in a hermetically sealed container and can be reconstituted, e.g., with water or saline to the appropriate concentration for administration to a subject. Preferably, the antibodies or fusion proteins are supplied as a dry sterile lyophilized powder in a hermetically sealed container at a unit dosage of at least 5 mg, more preferably at least 10 mg, at least 15 mg, at least 25 mg, at least 35 mg, at least 45 mg, at least 50 mg, or at least 75 mg. The lyophilized antibodies or antigen binding fragments should be stored at between 2 and 8 degrees C. in their original container and the antibodies should be administered within 12 hours, preferably within 6 hours, within 5 hours, within 3 hours, or within 1 hour after being reconstituted. In an alternative embodiment, antibodies or fusion proteins are supplied in liquid form in a hermetically sealed container indicating the quantity and concentration of the antibody, fusion protein, or conjugated molecule. Preferably, the liquid form of the antibodies or fusion proteins are supplied in a hermetically sealed container at least 1 mg/ml, more preferably at least 2.5 mg/ml, at least 5 mg/ml, at least 8 mg/ml, at least 10 mg/ml, at least 15 mg/kg, at least 25 mg/ml, at least 50 mg/ml, at least 100 mg/ml, at least 150 mg/ml, at least 200 mg/ml of the antibodies of fusion proteins.

[0265] The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the condition, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. For antibodies and fusion proteins, the dosage administered to a patient is typically 0.0001 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.0001 mg/kg and 20 mg/kg, 0.0001 mg/kg and 10 mg/kg, 0.0001 mg/kg and 5 mg/kg, 0.0001 and 2 mg/kg, 0.0001 and 1 mg/kg, 0.0001 mg/kg and 0.75 mg/kg, 0.0001 mg/kg and 0.5 mg/kg, 0.0001 mg/kg to 0.25 mg/kg, 0.0001 to 0.15 mg/kg, 0.0001 to 0.10 mg/kg, 0.001 to 0.5 mg/kg, 0.01 to 0.25 mg/kg or 0.01 to 0.10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies or fragments thereof, or fusion proteins may be reduced by enhancing uptake and tissue penetration of the antibodies or fusion proteins by modifications such as, for example, lipidation.

[0266] In certain embodiments, the therapeutic or prophylactic composition is a nucleic acid encoding an Ebola antibody or an antigen-binding fragment thereof. The nucleic acid can be administered in vivo to promote expression of its encoded antibody or fragment, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (See U.S. Pat. No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (See e.g., Joliot et al., 1991, Proc. Natl. Acad. Sci. USA 88:1864-1868), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression by homologous recombination.

[0267] The compositions include bulk drug compositions useful in the manufacture of pharmaceutical compositions (e.g., impure or non-sterile compositions) and pharmaceutical compositions (i.e., compositions that are suitable for administration to a subject or patient) which can be used in the preparation of unit dosage forms. Such compositions comprise a prophylactically or therapeutically effective amount of a prophylactic and/or therapeutic agent disclosed herein or a combination of those agents and a pharmaceutically acceptable carrier. Preferably, the disclosed compositions include a prophylactically or therapeutically effective amount of antibody or fusion protein and a pharmaceutically acceptable carrier.

[0268] In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete), excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.

[0269] Generally, the ingredients of compositions are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0270] The compositions can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include, but are not limited to, those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

[0271] One embodiment provides a pharmaceutical pack or kit comprising one or more containers filled with antibody or antigen binding fragment. Additionally, one or more other prophylactic or therapeutic agents useful for the treatment of a disease can also be included in the pharmaceutical pack or kit. One embodiment provides a pharmaceutical pack or kit including one or more containers filled with one or more of the ingredients of the pharmaceutical compositions. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[0272] The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises one or more antibodies or antigen binding fragments. In another embodiment, a kit further comprises one or more other prophylactic or therapeutic agents useful for the treatment of Ebola infection, in one or more containers.

Diagnostic Methods

[0273] The Ebola antibodies and their antigen-binding fragments disclosed herein can be used for diagnostic purposes, such as to detect, diagnose, or monitor Ebola infections. The invention provides for the detection or diagnosis of infection comprising: (a) assaying a sample for Ebola or in a tissue sample of a subject using one or more antibodies (or fragments thereof) that immunospecifically bind to Ebola particles comprising the epitopes; and (b) comparing the level of the Ebola with a control level, e.g., levels in normal tissue samples, whereby an increase or decrease in the assayed level of Ebola compared to the control level is indicative of the infection. Such antibodies and fragments are preferably employed in immunoassays, such as the enzyme linked immunosorbent assay (ELISA), the radioimmunoassay (MA) and fluorescence-activated cell sorting (FACS).

[0274] One embodiment relates to the use of such antibodies and fragments, and particularly such antibodies and fragments that bind to human Ebola, as reagents for detection of Ebola in a sample or at a site of in vivo dormancy. Thus, the antibodies and fragments of the present invention have utility in the detection and diagnosis of an infection in a human. In one embodiment, such diagnosis comprises: a) administering to a subject (for example, parenterally, subcutaneously, or intraperitoneally) an effective amount of a labeled antibody or antigen-binding fragment that immunospecifically binds to Ebola particles; b) waiting for a time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject where Ebola is (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled antibody in the subject, such that detection of labeled antibody above the background level indicates that the subject has the infection. In accordance with this embodiment, the antibody is labeled with an imaging moiety which is detectable using an imaging system known to one of skill in the art. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

[0275] Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

[0276] In one embodiment, monitoring of an infection is carried out by repeating the method for diagnosing the disease, disorder or infection, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

[0277] Presence of the labeled molecule can be detected in the subject using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the disclosed diagnostic methods include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

[0278] In a specific embodiment, the antibody or antigen binding fragment is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Pat. No. 5,441,050). In another embodiment, the antibody or antigen binding fragment is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the antibody or antigen binding fragment is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the antibody or antigen binding fragment is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MM).

Examples

[0279] Disclosed herein are monoclonal antibodies specific for the glycoprotein of Ebola virus that can be used as a neutralizing antibody, prophylactically treating those who have yet to develop symptoms, or for treating patients diagnosed with Ebola virus disease. In order to develop these antibodies, circulating B cells and plasma cells were collected from the blood of patients who had recovered from Ebola infection. The three cell populations (bulk activated B cells, bulk plasmablasts, and Ebola glycoprotein-binding B cells), were sorted so that virus-specific antibodies could be isolated. Antibody heavy and light chain variable region segments were then amplified by PCR from single sorted cells. These gene segments were cloned into expression vectors and the antibodies were produced and evaluated for their ability to neutralize Ebola virus infectivity in vitro. Over 1000 individual sequences were determined in order to identify 200 Ebola glycoprotein-binding antibodies. These were screened to determine their ability to neutralize Ebola virus in vitro.

[0280] Through in vitro studies, it was identified that several of the monoclonal antibodies that were generated have high affinity compared to the antibody component of ZMapp, monoclonal antibody for treating Ebola virus disease.

Tables below shows data for certain antibodies.

TABLE-US-00009 GP constuct antibody ELISA EC50 specificity used for ELISA 5.1.10B3 5.2 ng/ml (35 pM) New epitope Delta mucin 2.1.1D05 5.1 ng/ml (34 pM) New epitope Delta mucin 5.6.1A2 12 ng/ml (80 pM) Chalice base? Delta mucin 13C6 40 ng/ml (270 pM) Glycan cap Delta mucin 2G4 100 ng/ml (670 pM) Chalice base Delta mucin 1H3 400 ng/ml (2.7 nM) Glycan cap Delta mucin KZ52 40 ng/ml (270 pM) Chalice base Delta mucin 13F6 4 ng/ml (2.7 pM) Mucin domain Full length GP PRNT50 (ug/ml) for antibody Ebola Zaire (Kikwit strain) 5.6.c2618 (ATK-13) 0.0061 9.6.3A06 0.0488 5.1.13G03 0.0978 5.6.1A02 0.195 2.1.7G07 1.57 2.1.1D07 6.25 5.1.10B03 3.13 2.1.1D05 3.13 5.1.7D03 1.57 9.6.1A09 0.78125 9.6.3D06 1.57 2.10.1E06 0.78125

Neutralizing antibodies and their properties are as follows:

[0281] Antibody, 5.6.1A2, neutralizes Ebola virus in vitro with a PRNT50 value of below 100 ng/ml--this is comparable or superior to all previously described antibodies. The mouse protection data for 5.1.10B3 and 5.6.1A2 showed 80-90% protection when the antibodies were given one day prior to infection of the animals with Ebola virus, which is superior to the protection observed in previous studies. PRNT is a plaque reduction neutralization test standard for detecting and measuring antibodies that neutralize viruses; number represents the concentration of serum necessary to reduce the number of infected host cell plaques that form.

[0282] 5.1.10B3--antibody source: bulk plasmablasts from EVDS 1 month; PRNT*80 of 3 ug/ml and PRNT50 of 25 ug/ml; protected 8/10 mice. Escape mutations map to GP base.

[0283] 5.6.1A2--antibody source: GP binding cells from EVDS 6 months; PRNT80 of 98 ng/ml and PRNT50 not yet determined but less than 98 ng/ml; protected 9/10 mice. Escape mutations map to fusion loop.

[0284] 2.1.1D05--antibody source: GP binding cells from EVD2 1 month; in vitro neutralization potency not yet determined; protected 3/10 mice. Escape mutations map to glycan cap.

[0285] 2.1.1D07--antibody source: GP binding cells from EVD2 1 month.

[0286] 9.6.3D6--antibody source: GP binding cells from EVD9 6 months; in vitro neutralization.

[0287] Strain-relevant binding affinity:

[0288] Ebola Zaire (Mayinga) GP--all

[0289] Bundibugyo GP--5.6.1A2, 9.6.3D6

[0290] Reston GP--2.1.1D05, 2.1.1D07, 5.6.1A2

[0291] Sudan GP--2.1.1D07

Table of Data for Select Antibodies

TABLE-US-00010

[0292] % of mice protected 50% plaque 50% plaque from 100 p.f.u. reduction reduction Ebola challenge neutralization neutralization when antibody mAb epitope titer (PRNT50) titer (PRNT50) given 1 day prior name location for Ebola Zaire for Ebola Sudan to infection 2.1.1B02 mucin residues non- 100% 478-490 neutralizing protection 5.24.1C11 fusion loop <0.36 .mu.g/ml <0.36 .mu.g/ml 9.20.1C03 inner chalice <0.36 .mu.g/ml <0.36 .mu.g/ml bowl 5.24.1B03 glycan cap non- Binds all neutralizing filoviruses 9.20.1D09 chalice base <0.36 .mu.g/ml 0.78 .mu.g/ml 5.24.2A03 glycan cap non- Binds all neutralizing filoviruses 9.20.1A02 inner chalice <0.36 .mu.g/ml non- bowl neutralizing 5.24.2C05 chalice base <0.36 .mu.g/ml 6.25 .mu.g/ml 5.24.2B07 inner chalice 1.56 .mu.g/ml 12.5 .mu.g/ml bowl

Methods for production of the antibodies utilized protocols provided in the following references.

[0293] Wrammert et al. report using immunoglobulin variable regions isolated from sorted single ASCs to produce human monoclonal antibodies (mAbs) that bound with high affinity. Nature. 2008 May 29; 453(7195): 667-671. Smith et al. report a protocol for the production of antigen-specific human monoclonal antibodies (hmAbs) wherein antibody-secreting cells (ASCs) are isolated from whole blood collected after vaccination and sorted by flow cytometry into single cell plates. The antibody genes of the ASCs are then amplified by RT-PCR and nested PCR, cloned into expression vectors and transfected into a human cell line. See FIG. 1.

[0294] The complete sequence for a cloning vector for generating a chimeric antibody heavy chain with a human immunoglobulin G1 (AbVec-hIgG1) is found in GenBank ACCESSION FJ475055 which comprises a CMV promotor, murine IgG1 signal peptide, cloning site, Cgamma-1 (IgG1) constant region derived from Homo sapiens (SEQ ID NO: 66), followed by beta-lactamase which confers resistance to ampicillin.

[0295] In certain embodiments, antibodies or antigen binding fragments disclosed herein comprise a heavy chain constant region of with a sequence below or with a sequence having at least 80, 85, 90, 95, 98, 99%, or more identity or similarity. Heavy chain constant region sequence:

TABLE-US-00011 (SEQ ID NO: 66) RSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK.

[0296] In certain embodiments, antibody or antigen binding fragment comprises the N297A mutation:

TABLE-US-00012 (SEQ ID NO: 67) RSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

[0297] In certain embodiments, antibody or antigen binding fragment comprises the triple mutation M252Y/S254T/T256E mutation:

TABLE-US-00013 (SEQ ID NO: 68) RSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

Sequence CWU 1

1

2141107PRTArtificialSynthetic 1Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Phe 20 25 30Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ser Tyr Ile Ser Pro Phe 85 90 95Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 1052118PRTArtificialSynthetic 2Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr 20 25 30Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Val Arg Phe Gly Asp Thr Ala Val Asp Tyr Trp Gly Gln Gly Thr 100 105 110Leu Val Thr Val Ser Ser 1153113PRTArtificialSynthetic 3Asp Ile Val Met Thr Gln Ser Pro Arg Ser Leu Ser Val Thr Pro Gly1 5 10 15Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Arg 20 25 30Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75 80Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95Leu Gln Thr Pro Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110Lys4122PRTArtificialSynthetic 4Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Val Arg Ser Asn 20 25 30Tyr Leu Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Leu Ile Tyr Ser Gly Gly Leu Thr Ala Tyr Ala Asp Ser Val Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Leu Tyr Tyr Cys Ala 85 90 95Arg Val Ala Ser Ser Ala Gly Thr Phe Tyr Tyr Gly Met Asp Val Trp 100 105 110Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 1205112PRTArtificialSynthetic 5Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1 5 10 15Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65 70 75 80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Phe Asp Ser Ser 85 90 95Leu Arg Asp Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 1106120PRTArtificialSynthetic 6Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala 20 25 30Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Ala Ala Asp Tyr Ala Ala 50 55 60Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr65 70 75 80Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95Phe Cys Thr Thr Val Tyr Arg Tyr Asn Tyr Asp Ser Val Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115 1207108PRTArtificialSynthetic 7Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Phe Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Leu Tyr Gly Ser Ser Pro 85 90 95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 1058120PRTArtificialSynthetic 8Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile Ser Gly Ser Gly Gly Ile Thr Tyr Tyr Ala Asp Ser Val 50 55 60Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Arg Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Val Gly Glu Tyr Tyr Asp Phe Trp Ser Gly Tyr Ser Pro Phe 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu 115 1209108PRTArtificialSynthetic 9Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Arg Ile Asn Asn Leu 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Met Ile 35 40 45Tyr Asp Ala Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Asp Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr Asp Thr Asp Ser Gly 85 90 95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 10510129PRTArtificialSynthetic 10Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Tyr 20 25 30Ala Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45Ala Gly Ile Asn Lys Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val 50 55 60Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Lys Ser Leu Arg Ala Asp Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala Lys Glu Gly Ser Pro Leu Ser Asp Val Leu Leu Val Ala Ala Pro 100 105 110Phe Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser1111PRTArtificialSynthetic 11Arg Ala Ser Gln Ser Ile Ser Ser Phe Leu Asn1 5 10127PRTArtificialSynthetic 12Ala Ala Ser Ser Leu Gln Ser1 5139PRTArtificialSynthetic 13Gln Gln Ser Tyr Ile Ser Pro Phe Thr1 5149PRTArtificialSynthetic 14Phe Thr Phe Arg Ser Tyr Asp Met His1 51510PRTArtificialSynthetic 15Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro1 5 101610PRTArtificialSynthetic 16Val Arg Phe Gly Asp Thr Ala Val Asp Tyr1 5 101716PRTArtificialSynthetic 17Arg Ser Ser Gln Ser Leu Leu His Arg Asn Gly Tyr Asn Tyr Leu Asp1 5 10 15187PRTArtificialSynthetic 18Leu Gly Ser Asn Arg Ala Ser1 51910PRTArtificialSynthetic 19Met Gln Ala Leu Gln Thr Pro Ser Trp Thr1 5 10209PRTArtificialSynthetic 20Phe Ala Val Arg Ser Asn Tyr Leu Ser1 52116PRTArtificialSynthetic 21Leu Ile Tyr Ser Gly Gly Leu Thr Ala Tyr Ala Asp Ser Val Glu Gly1 5 10 152214PRTArtificialSynthetic 22Val Ala Ser Ser Ala Gly Thr Phe Tyr Tyr Gly Met Asp Val1 5 102314PRTArtificialSynthetic 23Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val Tyr1 5 10247PRTArtificialSynthetic 24Gly Asn Ser Asn Arg Pro Ser1 52512PRTArtificialSynthetic 25Gln Ser Phe Asp Ser Ser Leu Arg Asp Ser Trp Val1 5 10269PRTArtificialSynthetic 26Phe Thr Phe Ser Asn Ala Trp Met Asn1 52719PRTArtificialSynthetic 27Arg Ile Lys Ser Lys Thr Asp Gly Gly Ala Ala Asp Tyr Ala Ala Pro1 5 10 15Val Lys Gly289PRTArtificialSynthetic 28Val Tyr Arg Tyr Asn Tyr Asp Ser Val1 52912PRTArtificialSynthetic 29Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala1 5 10307PRTArtificialSynthetic 30Gly Ala Phe Asn Arg Ala Thr1 5319PRTArtificialSynthetic 31Gln Leu Tyr Gly Ser Ser Pro Trp Thr1 5329PRTArtificialSynthetic 32Phe Thr Phe Ser Thr Tyr Gly Met Ser1 53317PRTArtificialSynthetic 33Gly Ile Ser Gly Ser Gly Gly Ile Thr Tyr Tyr Ala Asp Ser Val Arg1 5 10 15Gly3416PRTArtificialSynthetic 34Val Gly Glu Tyr Tyr Asp Phe Trp Ser Gly Tyr Ser Pro Phe Glu Tyr1 5 10 153511PRTArtificialSynthetic 35Arg Ala Ser Gln Arg Ile Asn Asn Leu Val Ala1 5 10367PRTArtificialSynthetic 36Asp Ala Ser Ser Leu Lys Ser1 53710PRTArtificialSynthetic 37Gln Gln Tyr Asp Thr Asp Ser Gly Trp Thr1 5 10389PRTArtificialSynthetic 38Phe Thr Phe Ser Lys Tyr Ala Met Ile1 53917PRTArtificialSynthetic 39Gly Ile Asn Lys Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val Arg1 5 10 15Gly4020PRTArtificialSynthetic 40Glu Gly Ser Pro Leu Ser Asp Val Leu Leu Val Ala Ala Pro Phe Gly1 5 10 15Trp Phe Asp Pro 20417PRTArtificialSyntheticX(1)..(7)X is any amino acid 41Arg Xaa Ser Gln Xaa Ile Xaa1 5426PRTArtificialSyntheticX(1)..(6)X is any amino acid 42Arg Xaa Ser Gln Ser Xaa1 5436PRTArtificialSyntheticX(1)..(6)X is any amino acid 43Ala Ser Ser Leu Xaa Ser1 5446PRTArtificialSyntheticX(1)..(6)X is any amino acid 44Xaa Ser Asn Arg Xaa Ser1 5459PRTArtificialSyntheticX(1)..(9)X is any amino acid 45Gln Xaa Xaa Xaa Xaa Ser Pro Xaa Thr1 5466PRTArtificialSyntheticX(1)..(6)X is any amino acid 46Phe Xaa Xaa Arg Ser Xaa1 5478PRTArtificialSyntheticX(1)..(8)X is any amino acid 47Phe Thr Phe Xaa Xaa Tyr Xaa Met1 54811PRTArtificialSyntheticX(1)..(11)X is any amino acid 48Gly Xaa Xaa Xaa Tyr Xaa Xaa Ser Val Xaa Gly1 5 104910PRTArtificialSyntheticX(1)..(10)X is any amino acid 49Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr1 5 1050328PRTHomo sapiens 50Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser1 5 10 15Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe 20 25 30Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly 35 40 45Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu 50 55 60Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr65 70 75 80Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys 85 90 95Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 100 105 110Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 115 120 125Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 130 135 140Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr145 150 155 160Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 165 170 175Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 180 185 190Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 195 200 205Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 210 215 220Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu225 230 235 240Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 245 250 255Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 260 265 270Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 275 280 285Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 290 295 300Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln305 310 315 320Lys Ser Leu Ser Leu Ser Pro Gly 32551321DNAArtificialSynthetic 51gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca gagcattagc agctttttaa attggcatca gcagaaacca 120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240gaagattttg caatttacta ctgtcaacag agttacattt ccccattcac tttcggccct 300gggaccaaag tggatatcaa a 32152356DNAArtificialSynthetic 52gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccttcaga agctacgaca tgcactgggt ccgccaagct 120acaggaaaag gtctggagtg ggtctcagct attggtactg ctggtgacac atactatcca 180ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 240caaatgaaca gcctgagagc cgaggacacg gccgtgtatt actgtgcaag agtccgtttc 300ggggatacag ccgttgacta ctggggccag ggaaccctgg tcaccgtctc ctcagc 35653339DNAArtificialSynthetic 53gatattgtga tgactcagtc tccacgctcc ctgtccgtca cccctggaga gccggcctcc 60atctcctgca ggtctagtca gagcctcctg catagaaatg gatataacta tttggattgg 120tatctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240agcagagtgg aggctgaaga tgttggggtt tattactgca tgcaagctct acaaactccc 300tcgtggacgt tcggccaagg gaccaaggtg gaaatcaaa 33954368DNAArtificialSynthetic 54gaggtgcagc tggtggagtc aggaggaggc ttgatccagc ctggggggtc cctgagactc 60tcctgtgcag cctctggttt cgccgtcagg agcaactact tgagctgggt ccgccaggct 120cctgggaagg ggctggagtg ggtctcactt atttatagtg gtggtctcac agcctacgca 180gactccgtgg agggccggtt caccatctcc agagacaatt ctaagaacac actatatctt 240caaatgaaca gcctgagagt cgaggacacg gccctatatt actgtgcgag agtcgcatca 300tcggctggaa ccttctacta cggtatggac gtctggggcc aagggaccac ggtcaccgtc 360tcctcagc 36855336DNAArtificialSynthetic 55cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc 60tcctgcactg ggagcagttc caacatcggg gcaggttatg atgtatactg gtaccagcag 120cttccaggaa cagcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc 180cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc 240caggctgagg atgaggctga ttactactgc cagtcctttg acagcagcct gagagattct 300tgggtgttcg gcggggggac caagctgacc gtccta 33656362DNAArtificialSynthetic 56gaggtgcagc tggtggagtc tgggggaggc ttggtaaaac ctggggggtc ccttagactc 60tcctgtgcag cctctggatt cactttcagt aacgcctgga tgaactgggt ccgccaggct 120ccagggaagg ggctggagtg ggttggccgt

attaagagca aaactgatgg tggggctgca 180gactacgctg cacccgtgaa gggcagattc accatctcaa gagatgattc aaaaaacacg 240ctgtatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtaccaca 300gtctacagat acaactatga ttccgtctgg ggccagggaa ccctggtcac cgtctcctca 360gc 36257324DNAArtificialSynthetic 57gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa 120cctggccagg ctcccaggct cctcatctat ggtgcattta acagggccac tggcatccca 180gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag 240cctgaagatt ttgcagtgta ttactgtcag ctgtatggta gctcaccgtg gacgttcggc 300caagggacca aggtggaaat caaa 32458377DNAArtificialSynthetic 58gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt cacctttagc acctatggca tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg ggtctcaggt attagtggta gtggtggtat cacatactac 180gcagactccg tgaggggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240ctgcgaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagtgggg 300gagtattacg atttttggag tggttattcc ccctttgaat actggggcca gggaaccctg 360gtcaccgtct cctcagc 37759324DNAArtificialSynthetic 59gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggccagtca gaggattaat aatttggtgg cctggtatca gcagaaacca 120gggaaagccc ctaaggtcat gatctatgat gcctccagtt tgaaaagtgg ggtcccatca 180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct 240gatgattttg caacttattt ctgccaacag tatgatactg attcggggtg gacgttcggc 300caagggacca aggtggaaat caaa 32460389DNAArtificialSynthetic 60gaggtgcagc tgttggagtc tgggggaggc ctggtacagc cgggggggtc cctgagactc 60tcctgtgccg cctctggatt cacctttagc aaatatgcca tgatctgggt ccgccaggcc 120ccagggaagg ggctgcagtg ggtcgcaggt attaataaga gtggtggcag gacatactac 180gcagactccg tgaggggccg gttcaccatc tccagagaca attccaagaa tacgctgtac 240ctgcaaatga aaagcctgag agccgacgac acggccatgt attactgtgc gaaagaggga 300tcccctttat cagatgtttt actggtagca gctccatttg ggtggttcga tccctggggc 360cagggaaccc tggtcaccgt ctcctcagc 3896116PRTArtificialSyntheticX(1)..(16)X is any amino acid 61Tyr Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Leu1 5 10 1562150PRTArtificialSynthetic 62Ala Gln Leu Pro Ile Thr Glu Ala Gln Ser Phe Gly Leu Leu Asp Pro1 5 10 15Lys Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile 20 25 30Leu Thr Ala Leu Phe Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 35 40 45Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 50 55 60Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp65 70 75 80Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 85 90 95Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 100 105 110Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 115 120 125Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met 130 135 140Gln Ala Leu Pro Pro Arg145 15063151PRTArtificialSynthetic 63Ala Gln Leu Pro Ile Thr Glu Ala Gln Ser Phe Gly Leu Leu Asp Pro1 5 10 15Lys Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile 20 25 30Leu Thr Ala Leu Phe Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 35 40 45Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 50 55 60Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp65 70 75 80Pro Glu Met Gly Gly Lys Pro Gln Arg Arg Lys Asn Pro Gln Glu Gly 85 90 95Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu 100 105 110Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu 115 120 125Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His 130 135 140Met Gln Ala Leu Pro Pro Arg145 15064150PRTArtificialSynthetic 64Ala Gln Leu Pro Ile Thr Glu Ala Gln Ser Phe Gly Leu Leu Asp Pro1 5 10 15Lys Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile 20 25 30Leu Thr Ala Leu Phe Leu Arg Val Lys Phe Ser Arg Ser Ala Glu Pro 35 40 45Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 50 55 60Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp65 70 75 80Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 85 90 95Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 100 105 110Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 115 120 125Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met 130 135 140Gln Ala Leu Pro Pro Arg145 1506562PRTArtificialSynthetic 65Glu Pro Gln Leu Cys Tyr Ile Leu Asp Ala Ile Leu Phe Leu Tyr Gly1 5 10 15Ile Val Leu Thr Leu Leu Tyr Cys Arg Leu Lys Ile Gln Val Arg Lys 20 25 30Ala Ala Ile Thr Ser Tyr Glu Lys Ser Asp Gly Val Tyr Thr Gly Leu 35 40 45Ser Thr Arg Asn Gln Glu Thr Tyr Glu Thr Leu Lys His Glu 50 55 6066330PRTArtificialSynthetic 66Arg Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225 230 235 240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr305 310 315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 33067330PRTArtificialSynthetic 67Arg Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225 230 235 240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr305 310 315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 33068330PRTArtificialSynthetic 68Arg Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys 130 135 140Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150 155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225 230 235 240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr305 310 315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 33069108PRTArtificialSynthetic 69Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Phe Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro 85 90 95Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105707PRTArtificialSynthetic 70Gln Ser Val Ser Ser Ser Tyr1 5717PRTArtificialSynthetic 71Gly Ala Phe Asn Arg Ala Thr1 5729PRTArtificialSynthetic 72Gln Gln Tyr Gly Arg Ser Pro Phe Thr1 573125PRTArtificialSynthetic 73Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Thr Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Thr Gly Ser Gly Tyr Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Gly Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Ala Lys Val Gly Glu Tyr Tyr Asp Phe Trp Ser Gly Tyr Ser Pro Phe 100 105 110Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125748PRTArtificialSynthetic 74Gly Phe Ala Phe Ser Thr Tyr Ala1 5758PRTArtificialSynthetic 75Ile Thr Gly Ser Gly Tyr Ser Thr1 57618PRTArtificialSynthetic 76Ala Lys Val Gly Glu Tyr Tyr Asp Phe Trp Ser Gly Tyr Ser Pro Phe1 5 10 15Asp Ser77112PRTArtificialSynthetic 77Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Ala Val Thr Leu Gly1 5 10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Arg Leu Val His Ser 20 25 30Asp Gly Asn Thr Tyr Leu Ser Trp Leu His Gln Arg Pro Gly Gln Pro 35 40 45Pro Arg Leu Leu Ile Tyr Lys Val Ser Leu Arg Phe Ser Gly Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile65 70 75 80Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala 85 90 95Thr Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 1107811PRTArtificialSynthetic 78Gln Arg Leu Val His Ser Asp Gly Asn Thr Tyr1 5 10797PRTArtificialSynthetic 79Lys Val Ser Leu Arg Phe Ser1 5809PRTArtificialSynthetic 80Met Gln Ala Thr Gln Phe Pro Leu Thr1 581115PRTArtificialSynthetic 81Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Glu Tyr 20 25 30Met Met Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Thr Ser Thr Tyr Ile Asn Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg Gly Ser Thr Gly Gly Tyr Trp Gly Gln Gly Thr Leu Ile Thr 100 105 110Val Ser Ser 115828PRTArtificialSynthetic 82Gly Phe Thr Phe Asn Glu Tyr Met1

5838PRTArtificialSynthetic 83Ile Ser Gly Thr Ser Thr Tyr Ile1 5846PRTArtificialSynthetic 84Gly Ser Thr Gly Gly Tyr1 585107PRTArtificialSynthetic 85Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45Tyr Ser Ala Phe Ser Leu Gln Asn Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105868PRTArtificialSynthetic 86Gln Ser Ile Ser Ser Tyr Leu Asn1 5877PRTArtificialSynthetic 87Ser Ala Phe Ser Leu Gln Asn1 5889PRTArtificialSynthetic 88Gln Gln Ser Tyr Ser Thr Pro Arg Thr1 589116PRTArtificialSynthetic 89Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly1 5 10 15Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Thr 20 25 30Asn Trp Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45Ile Gly Glu Ile Tyr His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu 50 55 60Lys Ser Arg Val Thr Ile Ser Leu Asp Lys Ser Lys Asp Gln Phe Ser65 70 75 80Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Tyr Ser Asn Thr Trp Thr Gly Gly Trp Gly Gln Gly Thr Leu Val 100 105 110Thr Val Ser Ser 1159010PRTArtificialSynthetic 90Gly Ser Ile Ser Ser Thr Asn Trp Trp Ser1 5 10916PRTArtificialSynthetic 91His Ser Gly Ser Thr Asn1 5927PRTArtificialSynthetic 92Ser Asn Thr Trp Thr Gly Gly1 593107PRTArtificialSynthetic 93Glu Val Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Gly Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Arg Leu Leu Ile 35 40 45Tyr Asp Thr Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Thr Ile Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Lys Trp Gly Val 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105948PRTArtificialSynthetic 94Gln Ser Val Ser Gly Tyr Leu Ala1 5957PRTArtificialSynthetic 95Asp Thr Ser Asn Arg Ala Thr1 5969PRTArtificialSynthetic 96Gln Gln Arg Ser Lys Trp Gly Val Thr1 597124PRTArtificialSynthetic 97Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Asn Leu Ser Cys Lys Gly Ser Gly Tyr Ser Phe Arg Thr Tyr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Asn Ser Ser Gly Gly Gly Thr Thr Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75 80Met Glu Leu Arg Ser Leu Lys Tyr Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95Ala Arg Asp Arg Phe Pro Thr Val Ser Gly Glu Pro Phe Ala Met Asp 100 105 110Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 1209810PRTArtificialSynthetic 98Gly Tyr Ser Phe Arg Thr Tyr Tyr Ile His1 5 109910PRTArtificialSynthetic 99Ile Asn Ser Ser Gly Gly Gly Thr Thr Tyr1 5 1010015PRTArtificialSynthetic 100Asp Arg Phe Pro Thr Val Ser Gly Glu Pro Phe Ala Met Asp Val1 5 10 15101109PRTArtificialSynthetic 101Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ser Asn 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Val Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Ala Ser Pro 85 90 95Pro Tyr Ser Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 1051029PRTArtificialSynthetic 102Gln Ser Val Thr Ser Asn Tyr Leu Ala1 51037PRTArtificialSynthetic 103Gly Ala Ser Ser Arg Ala Thr1 510410PRTArtificialSynthetic 104Gln Gln Phe Gly Ala Ser Pro Pro Tyr Ser1 5 10105127PRTArtificialSynthetic 105Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Lys Phe 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Ile 35 40 45Ser Tyr Ile Ser Gly Gly Ser Lys Thr Lys Tyr Tyr Ala Asp Ser Val 50 55 60Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Gly Ser Leu Phe65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Phe Cys 85 90 95Ala Lys Lys Gly Trp Gln Ser Thr Phe Leu Gly Met Asp Tyr Phe Tyr 100 105 110Gly Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser 115 120 12510610PRTArtificialSynthetic 106Gly Phe Thr Phe Ser Lys Phe Ala Met Ser1 5 101079PRTArtificialSynthetic 107Ile Ser Gly Gly Ser Lys Thr Lys Tyr1 510820PRTArtificialSynthetic 108Ala Lys Lys Gly Trp Gln Ser Thr Phe Leu Gly Met Asp Tyr Phe Tyr1 5 10 15Gly Met Asp Val 20109113PRTArtificialSynthetic 109Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1 5 10 15Glu Arg Ala Ser Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Ser Ser 20 25 30Ser Asn Thr Lys Asn Tyr Leu Ala Trp Tyr Gln His Lys Pro Gly Gln 35 40 45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65 70 75 80Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95Tyr Tyr Gly Ala Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110Lys11012PRTArtificialSynthetic 110Gln Ser Val Leu Ser Ser Ser Asn Thr Lys Asn Tyr1 5 101117PRTArtificialSynthetic 111Trp Ala Ser Thr Arg Glu Ser1 51129PRTArtificialSynthetic 112Gln Gln Tyr Tyr Gly Ala Pro Tyr Thr1 5113118PRTArtificialSynthetic 113Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr 20 25 30Asp Met Asp Trp Phe Arg Gln Ser Thr Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Gly Ser Ala Gly Asp Thr Tyr Tyr Thr Asp Ser Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Glu Asn Gly Lys Asn Ser Leu Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Ala Arg Phe Gly Asp Asn Val Phe Asp Leu Trp Gly Arg Gly Thr 100 105 110Leu Val Thr Val Ser Ser 1151149PRTArtificialSynthetic 114Phe Thr Phe Arg Ser Tyr Asp Met Asp1 51157PRTArtificialSynthetic 115Ile Gly Ser Ala Gly Asp Thr1 511610PRTArtificialSynthetic 116Ala Arg Phe Gly Asp Asn Val Phe Asp Leu1 5 10117108PRTArtificialSynthetic 117Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Ala Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Gly Asn 20 25 30Tyr Phe Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Ser Ala Ala Ser Ser Arg Ala Thr Gly Val Pro Asp Arg Phe Ser 50 55 60Ala Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 1051188PRTArtificialSynthetic 118Ser Val Ser Gly Asn Tyr Phe Ala1 51197PRTArtificialSynthetic 119Ala Ala Ser Ser Arg Ala Thr1 51209PRTArtificialSynthetic 120Gln Gln Tyr Gly Ser Ser Pro Leu Thr1 5121118PRTArtificialSynthetic 121Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ala Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr 20 25 30Asp Met His Trp Val Arg Gln Val Thr Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Thr Gly Ser Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Glu Asn Asp Lys Ser Ser Leu Tyr Leu65 70 75 80Gln Met Ser Ser Leu Arg Gly Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Ala Ala Phe Gly Ser His Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110Leu Val Thr Val Ser Ser 1151229PRTArtificialSynthetic 122Phe Thr Phe Arg Ser Tyr Asp Met His1 512310PRTArtificialSynthetic 123Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Thr1 5 1012410PRTArtificialSynthetic 124Ala Ala Phe Gly Ser His Tyr Phe Asp Tyr1 5 10125108PRTArtificialSynthetic 125Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln1 5 10 15Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala 20 25 30Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Pro Val Ile Tyr 35 40 45Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu65 70 75 80Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ser Asp Ser Ser Gly Thr Tyr 85 90 95Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 1051266PRTArtificialSynthetic 126Ala Leu Pro Lys Gln Tyr1 51274PRTArtificialSynthetic 127Lys Asp Ser Glu112811PRTArtificialSynthetic 128Gln Ser Ser Asp Ser Ser Gly Thr Tyr Val Val1 5 10129120PRTArtificialSynthetic 129Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg His Asp Ser Ser Gly Tyr Asp Ala Phe Asp Ile Trp Gly Gln 100 105 110Gly Thr Met Val Thr Val Ser Ser 115 1201308PRTArtificialSynthetic 130Gly Tyr Thr Phe Thr Ser Tyr Tyr1 51318PRTArtificialSynthetic 131Ile Asn Pro Ser Gly Gly Ser Thr1 513213PRTArtificialSynthetic 132Ala Arg His Asp Ser Ser Gly Tyr Asp Ala Phe Asp Ile1 5 10133112PRTArtificialSynthetic 133Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly1 5 10 15Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30Asn Gly Tyr Asn Tyr Val Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ser Arg Ala Ser Gly Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75 80Ser Arg Val Glu Thr Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Gly 85 90 95Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 11013411PRTArtificialSynthetic 134Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr1 5 101354PRTArtificialSynthetic 135Leu Gly Ser Ser11369PRTArtificialSynthetic 136Met Gln Gly Leu Gln Thr Pro Leu Thr1 5137121PRTArtificialSynthetic 137Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Arg Thr Ser Gly Tyr Thr Phe Ser Ser Tyr 20 25 30Asn Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Val Ile Asn Pro Tyr Gly Arg Ser Thr Thr Leu Tyr Ala Arg Arg 50 55 60Phe Arg Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val65 70 75 80Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe 85 90 95Cys Gly Arg Leu Tyr Ser Gly Ala Pro Tyr Gly Leu Asp Val Trp Gly 100 105 110Gln Gly Ser Thr Val Thr Val Ser Ser 115 12013810PRTArtificialSynthetic 138Gly Tyr Thr Phe Ser Ser Tyr Asn Ile His1 5 101397PRTArtificialSynthetic 139Pro Tyr Gly Arg Ser Thr Thr1 514013PRTArtificialSynthetic 140Gly Arg Leu Tyr Ser Gly Ala Pro Tyr Gly Leu Asp Val1 5 10141113PRTArtificialSynthetic 141Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Ala Ser Leu Gly1 5 10 15Glu Arg Ala Thr Ile Ser Cys Lys Ser Ser His Ser Val Leu Tyr Ser 20 25 30Ser Asn Asn Lys Asp Phe Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60Pro Val Arg Phe Asn Gly Gly Gly Ser Gly Thr His Phe Thr Leu Thr65 70 75 80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95Tyr Phe Ser Ser Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile 100 105 110Lys14212PRTArtificialSynthetic 142His Ser Val Leu Tyr Ser Ser Asn Asn Lys Asp Phe1 5 101434PRTArtificialSynthetic 143Trp Ala Ser Thr11449PRTArtificialSynthetic 144Gln Gln Tyr Phe Ser Ser Pro Ile Thr1 5145124PRTArtificialSynthetic 145Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ala Cys Lys Val Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Ser Phe Gly Val Gly His Tyr Ser Gln Lys Phe 50 55 60Arg Asp Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Thr Thr Ala Phe65 70 75 80Leu Glu Leu Ser Ser Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Ala Ile Leu Gly Thr Phe Asn Trp Lys Ser Gly Gly

Asn Tyr Phe Gly 100 105 110Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 1201468PRTArtificialSynthetic 146Gly Gly Thr Phe Ser Ser Tyr Thr1 51478PRTArtificialSynthetic 147Ile Ile Pro Ser Phe Gly Val Gly1 514817PRTArtificialSynthetic 148Ala Ile Leu Gly Thr Phe Asn Trp Lys Ser Gly Gly Asn Tyr Phe Gly1 5 10 15Pro149107PRTArtificialSynthetic 149Glu Ile Val Leu Thr Gln Ser Pro Asn Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Leu Arg Thr Asn 20 25 30Gln Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile His Thr Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Ala Ser Asp Thr Ser Ser Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Arg 100 1051506PRTArtificialSynthetic 150Gln Ser Leu Arg Thr Asn1 51514PRTArtificialSynthetic 151His Thr Ser Thr11529PRTArtificialSynthetic 152Gln Ala Ser Asp Thr Ser Ser Leu Thr1 5153125PRTArtificialSynthetic 153Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Ser Leu Ser Leu Thr Cys Thr Ile Ser Gly Gly Ser Ile Arg Asp Tyr 20 25 30Tyr Trp Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Tyr Lys Tyr His Ala Ala Arg Gly Asn Ser Asn Pro Ser Leu Glu 50 55 60Ser Arg Val Thr Met Ser Ile Asp Thr Ser Arg Ser Glu Phe Ser Leu65 70 75 80Arg Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Val Gln Tyr Gly Pro Gly Gly Gly Tyr Tyr Ser Gly Asn Trp Leu 100 105 110Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 1251548PRTArtificialSynthetic 154Gly Gly Ser Ile Arg Asp Tyr Tyr1 51557PRTArtificialSynthetic 155Lys Tyr His Ala Ala Arg Gly1 515619PRTArtificialSynthetic 156Ala Arg Val Gln Tyr Gly Pro Gly Gly Gly Tyr Tyr Ser Gly Asn Trp1 5 10 15Leu Asp Leu157106PRTArtificialSynthetic 157Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ala Thr Asn 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Val Leu Ile 35 40 45Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Thr Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu Asp Phe Ala Ile Tyr Tyr Cys His Gln Tyr His Ser Trp Arg Thr 85 90 95Phe Gly Gln Gly Thr Lys Val Glu Met Lys 100 1051586PRTArtificialSynthetic 158Gln Ser Ile Ala Thr Asn1 51594PRTArtificialSynthetic 159Gly Ala Ser Thr11608PRTArtificialSynthetic 160His Gln Tyr His Ser Trp Arg Thr1 5161122PRTArtificialSynthetic 161Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ala Ser Ser 20 25 30Asn Asp Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Pro Glu 35 40 45Trp Ile Gly Thr Ile Phe Tyr Arg Gly Thr Thr Asp Tyr Asn Pro Ser 50 55 60Leu Lys Ser Arg Leu Thr Met Ser Val Asp Thr Ser Arg Asn Gln Phe65 70 75 80Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Arg Leu Pro Leu Trp Phe Ser Glu Leu Gly His Asp Tyr Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12016210PRTArtificialSynthetic 162Gly Gly Ser Val Ala Ser Ser Asn Asp Tyr1 5 101637PRTArtificialSynthetic 163Ile Phe Tyr Arg Gly Thr Thr1 516414PRTArtificialSynthetic 164Ala Arg Leu Pro Leu Trp Phe Ser Glu Leu Gly His Asp Tyr1 5 10165111PRTArtificialSynthetic 165Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln1 5 10 15Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Val Tyr 20 25 30Asn Ser Val Ser Trp Tyr Arg Gln His Pro Gly Lys Val Pro Lys Leu 35 40 45Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu65 70 75 80Gln Ala Asp Asp Glu Gly Asp Tyr Tyr Cys Cys Ser Cys Ser Gly Thr 85 90 95Asn Ser Leu Cys Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 1101669PRTArtificialSynthetic 166Ser Ser Asp Val Gly Val Tyr Asn Ser1 51674PRTArtificialSynthetic 167Glu Val Ser Lys116811PRTArtificialSynthetic 168Cys Ser Cys Ser Gly Thr Asn Ser Leu Cys Val1 5 10169124PRTArtificialSynthetic 169Gln Val Gln Leu His Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Thr Asn Tyr 20 25 30Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Tyr Met Tyr Tyr Ser Ala Ser Ala His Tyr Asn Pro Ser Leu Gln 50 55 60Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 85 90 95Arg Val Asp Tyr Ser Ser Ser Ser Tyr Tyr Ser Gly Asn Trp Phe Asp 100 105 110Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 1201708PRTArtificialSynthetic 170Gly Asp Ser Ile Thr Asn Tyr Tyr1 51717PRTArtificialSynthetic 171Met Tyr Tyr Ser Ala Ser Ala1 517218PRTArtificialSynthetic 172Ala Arg Val Asp Tyr Ser Ser Ser Ser Tyr Tyr Ser Gly Asn Trp Phe1 5 10 15Asp Pro173112PRTArtificialSynthetic 173Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1 5 10 15Thr Val Thr Ile Ser Cys Thr Gly Ser Tyr Ser Asn Ile Gly Ala Gly 20 25 30Tyr Asp Val Gln Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45Leu Ile Tyr Asp Asn Val His Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65 70 75 80Gln Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Arg 85 90 95Leu Arg Asp Gln Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 1101749PRTArtificialSynthetic 174Tyr Ser Asn Ile Gly Ala Gly Tyr Asp1 51754PRTArtificialSynthetic 175Asp Asn Val His117612PRTArtificialSynthetic 176Gln Ser Tyr Asp Ser Arg Leu Arg Asp Gln Trp Val1 5 10177122PRTArtificialSynthetic 177Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Leu Ser Gly Val 20 25 30Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Arg Ile Lys Ser Thr Ser Asp Gly Gly Arg Ala Asp Phe Ala Ala 50 55 60Pro Ala Arg Gly Arg Phe Thr Met Ser Arg Asp Glu Ser Lys Asn Lys65 70 75 80Leu Phe Leu Gln Met Asn Asn Leu Gly Ile Glu Asp Thr Gly Met Tyr 85 90 95Tyr Cys Phe Thr Arg Val Gln Arg Asp Gly Thr Lys Asp Asp Phe Trp 100 105 110Gly Arg Gly Thr Leu Val Thr Val Ser Ser 115 1201788PRTArtificialSynthetic 178Gly Ile Thr Leu Ser Gly Val Trp1 517910PRTArtificialSynthetic 179Ile Lys Ser Thr Ser Asp Gly Gly Arg Ala1 5 1018013PRTArtificialSynthetic 180Phe Thr Arg Val Gln Arg Asp Gly Thr Lys Asp Asp Phe1 5 10181107PRTArtificialSynthetic 181Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln1 5 10 15Ser Ile Thr Leu Ser Cys Thr Val Gly Gly Asn Lys Phe Val Ser Trp 20 25 30Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Ser Asp Phe 35 40 45Thr Asp Arg Pro Ser Gly Val Ser Ser Arg Phe Ser Gly Ser Lys Ser 50 55 60Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Pro Asp Asp Glu65 70 75 80Ala Thr Tyr Phe Cys Ser Ser Tyr Ala Ser Thr Ser Thr Ser Leu Trp 85 90 95Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 1051828PRTArtificialSynthetic 182Cys Thr Val Gly Gly Asn Lys Phe1 51834PRTArtificialSynthetic 183Asp Phe Thr Asp118412PRTArtificialSynthetic 184Ser Ser Tyr Ala Ser Thr Ser Thr Ser Leu Trp Val1 5 10185125PRTArtificialSynthetic 185Gln Glu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Val Ser Gly Ser 20 25 30Tyr Phe Trp Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45Leu Gly Phe Ile His Ser Thr Gly Ser Thr Asn Thr Asn Pro Ser Leu 50 55 60Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser65 70 75 80Leu Arg Leu Thr Ser Val Ser Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Ala Ala Trp Leu Val Gly Gly Glu Tyr Tyr Asn Tyr Gly Met 100 105 110Asp Leu Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 1251869PRTArtificialSynthetic 186Gly Val Ser Val Ser Gly Ser Tyr Phe1 51877PRTArtificialSynthetic 187Ile His Ser Thr Gly Ser Thr1 518818PRTArtificialSynthetic 188Ala Arg Ala Ala Trp Leu Val Gly Gly Glu Tyr Tyr Asn Tyr Gly Met1 5 10 15Asp Leu189107PRTArtificialSynthetic 189Gly Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Tyr Thr Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Val 35 40 45Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 1051906PRTArtificialSynthetic 190Gln Gly Ile Tyr Thr Tyr1 51914PRTArtificialSynthetic 191Val Ala Ser Tyr11929PRTArtificialSynthetic 192Gln Gln Leu Asn Ser Tyr Pro Leu Thr1 5193127PRTArtificialSynthetic 193Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Phe Ile Trp Tyr Asp Gly Thr Ile Gln Tyr Tyr Gly Asp Ser Val 50 55 60Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ser Thr Leu Tyr Arg Asn Gly Asp Tyr Gly Ser Gly Ser Arg Thr 100 105 110Pro Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 1251948PRTArtificialSynthetic 194Gly Phe Thr Phe Ser Ser Tyr Gly1 51958PRTArtificialSynthetic 195Ile Trp Tyr Asp Gly Thr Ile Gln1 519620PRTArtificialSynthetic 196Ala Ser Thr Leu Tyr Arg Asn Gly Asp Tyr Gly Ser Gly Ser Arg Thr1 5 10 15Pro Asp Asp Tyr 20197360DNAArtificialSynthetic 197gaggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60tcctgcaagg catctggata caccttcacc agctactata tgcactgggt gcgacaggcc 120cctggacaag ggcttgagtg gatgggaata atcaacccta gtggtggtag cacaagctac 180gcacagaagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac 240atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc taggcatgat 300agtagtggtt atgatgcttt tgatatctgg ggccaaggga caatggtcac cgtctcttca 360198324DNAArtificialSynthetic 198tcctatgagc tgacacagcc accctcggtg tcagtgtccc caggacagac ggccaggatc 60acctgctctg gagatgcatt gccaaagcaa tatgcttatt ggtaccagca gaagccaggc 120caggcccctg tgccggtgat atataaagac agtgagaggc cctcagggat ccctgagcga 180ttctctggct ccagctcagg gacaacagtc acgttgacca tcagtggagt ccaggcagaa 240gacgaggctg actattactg tcaatcatca gacagcagtg gtacttatgt ggtattcggc 300ggagggacca agctgaccgt ccta 324199363DNAArtificialSynthetic 199caggtgcaac tggtgcagtc aggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60tcctgcagga catctggata cacattctcc agctacaata tacattgggt gcgacaggcc 120cctggacaag gtcttgagtg gatgggagtt attaatcctt atggccgtag taccacactt 180tacgcacgga ggttccggga cagagtcacc atgaccaggg acacgtccac gagcacagtt 240tacatggaac tgagcagcct gagatccgag gacacggccg tatacttctg tggaaggctt 300tacagtggtg caccctatgg tttggacgtc tggggccaag ggagcacggt caccgtctct 360tca 363200336DNAArtificialSynthetic 200gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tgtggattgg 120tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc tagtcgggcc 180tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240agcagagtgg agactgagga tgttggcatt tattactgca tgcaaggtct acaaactccc 300ctcactttcg gcggagggac caaggtggag atcaaa 336201372DNAArtificialSynthetic 201caggtgcagc tggtgcagtc tggggctgaa gtgaagaagc ctgggtcctc ggtgaaggtc 60gcctgcaagg tttctggagg caccttcagc agctatacta ttagttgggt gcgacaggcc 120cctggacaag ggcttgagtg gatgggaggg atcatccctt cctttggtgt gggacactac 180tcacagaagt tccgggacag agtcacgcta accgcggaca aatccacgac cacagccttc 240ttggaactga gcagcgtgag atctgaagac acggccctat attactgtgc gatactgggg 300acttttaact ggaagtccgg gggcaactac ttcggcccct ggggccaggg gaccctggtc 360accgtctctt ca 372202339DNAArtificialSynthetic 202gacatcgtgc tgacccagtc tccagactcc ctggctgcgt ctctgggcga gagggccacc 60atcagctgca agtccagcca cagtgtttta tacagctcca acaataagga cttctttgcc 120tggtaccagc agaaaccagg acagcctccc aaactgctca tttcctgggc atctacccgg 180gaatccgggg tccctgtccg attcaatggc ggcgggtctg ggacacattt cactctcacc 240atcagcagcc tgcaggctga agatgtggca gtttactact gtcagcaata ttttagttct 300ccgatcacct tcggccaagg gacacgactg gagattaaa 339203375DNAArtificialSynthetic 203caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagag cctgtccctc 60acatgcacta tctctggcgg ctccataagg gactattact ggagctggat tcggcaggcc 120ccagggaagg gactggagtg gatcggatat aagtatcacg ctgcgcgcgg caactccaat 180ccctccctcg agagtcgagt caccatgtcc atcgacacgt ccaggagcga gttctccctg 240aggctgactt ctgtgaccgc tgcggacacg gccgtctatt attgtgcgag agttcaatac 300ggtcctgggg gcggttacta ttcggggaac tggttggacc tctggggcca gggaaccctg 360gtcaccgtct cttca 375204321DNAArtificialSynthetic 204gaaattgtgt tgacacagtc tccaaacacc ctgtctttgt ctccagggga aagagccacc

60ctctcctgca gggccagtca gagtcttcgt accaaccagt tagcctggta ccagcaaaaa 120cctggccagg ctcccaggct cctcatccat acatccacca gggccactgg catcccagac 180aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcgg actggaggct 240gaagactttg cagtgtatta ctgtcaggcg tctgatacct catcgctcac tttcggcgga 300gggaccaagt tagagatcag a 321205366DNAArtificialSynthetic 205cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60acctgcactg tctctggtgg ctccgtcgcc agtagtaatg actactgggg ctggatccgc 120cagcccccag ggaaggggcc ggagtggatt gggactatct tttatagagg gaccaccgac 180tacaacccgt ccctcaagag tcgactcact atgtccgtgg acacgtccag gaaccagttc 240tccctgaagc tgagctctgt gaccgccgca gacacggctg tctattactg tgcgagactg 300cccctatggt tcagtgagtt aggtcatgac tactggggcc agggaaccct ggtcaccgtc 360tcctca 366206407DNAArtificialSynthetic 206gaaatagtga tgacgcagtc tccagccacc ctgtctctgt ctccaggaga aagagcctcc 60ctgtcctgca gggccagtca gagtattgcc accaacttag cctggtacca gcaaaaacct 120ggccagcctc ccagggtcct catctatggt gcatccacaa gggcaactgg tatcccaacc 180aggttcagtg gcagtggatc tgggacagag ttcactctca ccatcagcag cctgcagtct 240gaagattttg caatttatta ctgtcaccag tatcatagct ggcggacgtt cggccaaggg 300accaaggtag aaatgaaagt gcgagagtgg actacagttc gagtagttat tattcgggaa 360actggttcga cccctggggc cagggaaccc ttgtcaccgt ctcctca 407207372DNAArtificialSynthetic 207caggtgcagc tgcatgagtc gggcccaggg ctggtgcagc cttcggagac cctgtccctc 60acctgcactg tctctggtga ctccatcact aattactact ggagctggat ccggcagccc 120ccagggaagg gactggagtg gattggatat atgtattaca gtgcgagcgc ccactacaat 180ccctccctcc agagtcgagt caccatttca gtggacacgt ccaagaacca gttctccctg 240aaactgagct ctgtgaccgc tgcggacacg gccgtgtatt tctgtgcgag agtggactac 300agttcgagta gttattattc gggaaactgg ttcgacccct ggggccaggg aacccttgtc 360accgtctcct ca 372208333DNAArtificialSynthetic 208cagtctgccc tgactcagcc tccctccgcg tccgggtctc ctggacagtc agtcaccatc 60tcctgcactg gaaccagcag tgacgttggt gtttataatt ctgtctcctg gtaccgacag 120cacccaggca aagtccccaa actcatgatt tatgaggtca gtaagcggcc ctcaggggtc 180cctgatcgct tctctggctc caagtccggc aacacggcct ccctgaccgt ctctgggctc 240caggctgacg atgagggtga ttattactgc tgctcatgtt caggcaccaa cagcctctgt 300gtcttcggaa ctgggaccaa ggtcaccgtc ctg 333209366DNAArtificialSynthetic 209gaggtgcagc tggtggagtc tgggggagac ttagtacagc ctggggggtc cctcagactc 60tcctgtgcag cctctggaat caccttgagt ggagtttgga tgaactgggt ccgccaggct 120ccagggaagg ggctggagtg gattggccgt attaaaagca caagtgacgg tgggagagca 180gacttcgccg cacccgcgag aggcagattc accatgtcaa gagatgagtc aaagaataag 240ctgtttctgc aaatgaacaa cctgggaatc gaagacacag gcatgtatta ttgtttcacg 300agagtccaaa gagacggaac taaagatgac ttctggggcc ggggaaccct ggtcaccgtc 360tcttca 366210336DNAArtificialSynthetic 210cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagac ggtcaccatc 60tcctgcactg ggagctactc caacatcggg gcaggttatg atgtacagtg gtaccagcac 120cttcctggaa cagcccccaa actcctcatt tatgataatg tccatcggcc ctcaggggtc 180cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc 240cagactgaag atgaggctga ttattattgc cagtcctatg acagcagact gagggatcaa 300tgggtgttcg gcggagggac caagctgacc gtccta 336211375DNAArtificialSynthetic 211caggagcagc tgcaagagtc gggcccagga ctggtgaagc cttcggggac cctgtccctc 60acctgcactg tctccggcgt ctccgtcagt gggagttact tctggaattg ggtccgccag 120cccccaggga agggactgga gtggcttgga tttattcata gcactgggag caccaacacc 180aacccctccc tcaagagtcg agtcaccatt tcagtagaca cgtccaagaa ccagttctcc 240ctgaggctga cttctgtgag cgctgcggac acggccgttt attactgtgc gagagccgct 300tggttagtag ggggggagta ctacaactac ggtatggacc tttggggcca agggaccacg 360gttaccgtct cctca 375212321DNAArtificialSynthetic 212cagtctgccc tgactcagcc cgcctccgtt tctgggtctc ctggacagtc gatcaccctc 60tcctgcactg taggcggtaa taagtttgtc tcttggtatc aacaacaccc aggcaaagcc 120cccaaactca ttatttctga tttcactgat cggccctcag gggtctctag tcgcttctct 180ggctccaagt ctggcaacac ggcctccctg accatctctg ggctccagcc tgacgacgag 240gctacttatt tctgcagttc ttacgcaagc accagcactt ctctttgggt cttcggcggg 300gggaccaagc tgaccgtcct a 321213381DNAArtificialSynthetic 213caggtgcagc tggtggaatc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60tcctgtgtag cgtctggatt caccttcagt agttatggca tgcactgggt ccgccaggct 120ccaggcaagg ggctggagtg ggtggcattt atatggtatg atggaactat tcaatactat 180ggagactccg tgaagggccg attcatcatc tccagagaca attccaggaa tacgctgtat 240ctacaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagcactctt 300taccgaaacg gtgactacgg gtcagggtcc cggaccccgg acgactactg gggccaggga 360accctggtca ccgtctcttc a 381214321DNAArtificialSynthetic 214ggcatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggccagtca gggcatttac acttatttag cctggtatca gcaaaaacca 120gggaaagccc ctaagctcct ggtctatgtt gcatccactt tgcaaagtgg ggtcccatca 180aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240gaagattttg caacttatta ctgtcaacag cttaatagtt accctctcac ttttggccag 300gggaccaagc tggagatcaa a 321

Claims

1. A non-naturally occurring chimeric antibody or antigen binding fragment comprising six complementarity determining regions (CDRs), wherein the CDRs comprise the three light chain CDRs or derivatives of an antibody selected from 5.1.10B3, 5.6.1A02, 2.1.1D05, 2.1.1D07, 9.6.3D06, 2.1.7G07, 9.6.3A06, 5.1.13G03, 5.6.c2618, 2.10.1E06, 9.6.1A09, 5.1.7D03, wherein the CDRs comprise the three heavy chain CDRs or derivatives of an antibody selected from 5.1.10B3, 5.6.1A02, 2.1.1D05, 2.1.1D07, 9.6.3D06, 2.1.7G07, 9.6.3A06, 5.1.13G03, 5.6.c2618, 2.10.1E06, 9.6.1A09, 5.1.7D03, and wherein the antibody or antigen binding fragment thereof binds to an epitope expressed in an Ebola virus particle.

2. The antibody or antigen fragment of claim 1, wherein the antibody, antigen binding fragment, the light chain, or the heavy chain comprises a non-naturally occurring chimeric amino acid sequence such that there is at least one mutation that is not present in naturally occurring antibodies comprising the six CDRs.

3. The antibody of antigen binding fragment of claim 1 comprising a human constant domain from an immunoglobulin constant region (Fc) having one, two, three, four, five, six, or more of the following mutations: G236A, S239D, A330L, I332E, S267E, L328F, P238D, H268F, S324T, S228P, G236R, L328R, L234A, L235A, M252Y, S254T, T256E, M428L, N434S, A330L, N297A, and N297Q.

4. The antibody or antigen fragment of claim 1 comprising at least one amino acid substitution in the heavy chain constant region that is not present in naturally occurring antibodies comprising the six CDRs.

5. The antibody of claim 1, wherein the heavy chain comprises a sequence in a constant region that is different from any sequences present in naturally derived antibodies for which the light chain variable region comprise the three light chain CDRs and the heavy chain variable region comprise the three light chain CDRs.

6. The antibody or antigen binding fragment thereof of claim 1, wherein the epitope expressed on an Ebola virus particle is arrayed on a surface, expressed on the surface of a cell, or expressed at an endogenous or transfected concentration, and the antibody or antigen binding fragment is bound to the epitope.

7. A nucleic acid encoding an antibody or antigen binding fragment of claim 1, vector, or expression system composed therein.

8. A pharmaceutical composition comprising the antibody or antigen binding fragment thereof of claim 1, and a physiologically acceptable carrier or excipient.

9. A method of detection Ebola virus infection, comprising: (a) assaying the expression of Ebola virus epitope in cells or in a tissue sample of a subject using the antibody or antigen binding fragment thereof of claim 1 and (b) comparing the level of the Ebola virus epitope with a control level, wherein an increase in the assayed level of Ebola virus compared to the control level is indicative of the infection.

10. A method of preventing or treating an Ebola virus infection comprising administering an effective amount of a pharmaceutical composition of claim 8 to a subject in need thereof.

11. A non-naturally occurring chimeric antibody or antigen binding fragment comprising six complementarity determining regions (CDRs), wherein the CDRs comprise the three light chain CDRs or derivatives of an antibody selected from 2.1.1B02, 5.24.1C11, 9.20.1C03, 5.24.1B03, 9.20.1D09, 5.24.2A03, 9.20.1A02, 5.24.2C05, and 5.24.2B07, wherein the CDRs comprise the three heavy chain CDRs or derivatives of an antibody selected from 2.1.1B02, 5.24.1C11, 9.20.1C03, 5.24.1B03, 9.20.1D09, 5.24.2A03, 9.20.1A02, 5.24.2C05, and 5.24.2B07, and wherein the antibody or antigen binding fragment thereof binds to an epitope expressed in an Ebola virus particle.

12. The antibody or antigen fragment of claim 11 wherein the antibody, antigen binding fragment, the light chain, or the heavy chain comprises a non-naturally occurring chimeric amino acid sequence such that there is at least one mutation that is not present in naturally occurring antibodies comprising the six CDRs.

13. The antibody of antigen binding fragment of claim 11 comprising a human constant domain from an immunoglobulin constant region (Fc) having one, two, three, four, five, six, or more of the following mutations: G236A, S239D, A330L, I332E, S267E, L328F, P238D, H268F, S324T, S228P, G236R, L328R, L234A, L235A, M252Y, S254T, T256E, M428L, N434S, A330L, N297A, and N297Q.

14. The antibody or antigen fragment of claim 11 comprising at least one amino acid substitution in the heavy chain constant region that is not present in naturally occurring antibodies comprising the six CDRs.

15. The antibody of claim 11, wherein the heavy chain comprises a sequence in a constant region that is different from any sequences present in naturally derived antibodies for which the light chain variable region comprise the three light chain CDRs and the heavy chain variable region comprise the three light chain CDRs.

16. The antibody or antigen binding fragment thereof of claim 11, wherein the epitope expressed on an Ebola virus particle is arrayed on a surface, expressed on the surface of a cell, or expressed at an endogenous or transfected concentration, and the antibody or antigen binding fragment is bound to the epitope.

17. A nucleic acid encoding an antibody or antigen binding fragment of claim 11, vector, or expression system, composed therein.

18. A pharmaceutical composition comprising the antibody or antigen binding fragment thereof of claim 11, and a physiologically acceptable carrier or excipient.

19. A method of detection Ebola virus infection, comprising: (a) assaying the expression of Ebola virus epitope in cells or in a tissue sample of a subject using the antibody or antigen binding fragment thereof of claim 11 and (b) comparing the level of the Ebola virus epitope with a control level, wherein an increase in the assayed level of Ebola virus compared to the control level is indicative of the infection.

20. A method of preventing or treating an Ebola virus infection comprising administering an effective amount of a pharmaceutical composition of claim 18 to a subject in need thereof.